The fecal metabolome and microbiome are altered in dogs with idiopathic epilepsy compared to healthy dogs

The fecal metabolome and microbiome are altered in dogs with idiopathic epilepsy compared to healthy dogs | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The fecal metabolome and microbiome are altered in dogs with idiopathic epilepsy compared to healthy dogs Fien Verdoodt, Myriam Hesta, Evy Goossens, Filip Van Immerseel, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5953419/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 25 Jul, 2025 Read the published version in Scientific Reports → Version 1 posted 4 You are reading this latest preprint version Abstract Idiopathic epilepsy (IE) is the most common chronic neurological disease in dogs, and a natural animal model for human epilepsy types with genetic and unknown etiology. The microbiota-gut-brain axis (MGBA) is a promising target for improving brain health in individuals where brain function is hampered. It's role in the pathophysiology of epilepsy remains however unclear. We aimed to identify differences in fecal metabolome and microbiome between healthy and dogs with IE. To this purpose, fecal samples of healthy (n = 39) and dogs with IE (n = 49) were metabolically profiled (n = 148 metabolites) and fingerprinted (n = 3690 features) using liquid chromatography coupled to mass spectrometry, and the bacterial phylogeny examined using 16S rRNA sequencing. Dogs with IE were categorized as drug-resistant (DR) (n = 27) or mild phenotype (MP) (n = 22). In dogs with DR IE, fecal metabolites such as histamine ( P = 0.022) and microbiome genera such as Escherichia-Shigella ( P = 0.021) increased, associated with a proinflammatory environment. In dogs with MP IE, alterations associated with anti-inflammatory properties, such as increased fecal serotonin ( P = 0.034) and Blautia hominis ( P = 0.012) were revealed. Overall, a role for the MGBA communication in canine IE was established. Health sciences/Neurology/Neurological disorders/Epilepsy Health sciences/Gastroenterology/Gastrointestinal system Health sciences/Medical research/Translational research Epilepsy Gut-Brain-Axis Metabolomics Microbiomics Canine Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 INTRODUCTION Epilepsy is a chronic non-communicable disease of the brain that is characterized by recurring spontaneous seizures. It affects 50 million people worldwide 1 , with a detrimental effect on the quality of life of people with the disease as well as their families 2 , 3 . Moreover, one-third of people with epilepsy cannot achieve a life without seizures with the currently available antiseizure medication (ASM) 4 . In 32% of cases, the etiology of human epilepsy remains unknown 5 , highlighting important knowledge gaps. Further exploration of mechanisms involved in epilepsy, such as e.g. the microbiota‒gut‒brain axis (MGBA), is therefore needed. The MGBA comprises complex bidirectional communication between the gastrointestinal (GI) system and central nervous system (CNS) via neuroanatomical pathways, endocrine, immune and metabolic signaling 5 . The importance and effect of the bidirectional connection between the intestinal microbiome and brain health has been documented for e.g. Parkinson’s disease 6 , major depression 7 and Alzheimer’s disease 8 . As such, the MGBA is an interesting and very promising target for improving brain health in individuals where brain function is hampered, such as those with epilepsy. In epilepsy specifically, research on the MGBA has focused on inflammatory signaling and neuroinflammation 9 . Other pathways such as neurotransmitter and amino acid metabolism are however also likely involved in the MGBA communication in epilepsy. These pathways can be studied by applying holistic omics approaches. By concurrently analyzing microbial composition, i.e. through microbiomics, and the resulting metabolic outputs, i.e. through metabolomics, an integrative approach enabling a multi-layered view of the biochemical environment within the GI system can be obtained, revealing functional insights that surpass those achieved through single-omics studies 10 . Canine idiopathic epilepsy (IE) serves as an established animal model for human epilepsy types with genetic and unknown etiologies 11 . Canine and human epilepsy share similar electrophysiological and pharmacological characteristics 11 , in addition to clinical features such as status epilepticus and behavioral comorbidities 12 . Pets moreover often share their living environment with humans, leading to a largely similar exposome, i.e. the whole of nongenetic environmental drivers for health and disease 13 . The nutritional management of pets offers a significant advantage, being that a standardized nutritional background can be easily implemented. Dogs can be fed an identical qualitatively balanced kibble diet that meets their nutritional requirements, thus ruling out nutritional inadequacies. This is particularly important in omics studies, where nutrition is a major and highly variable, environmental determinant 14 . As in humans with epilepsy, one third of dogs with IE are inadequately managed with ASM 15 , indicating the need for novel approaches such as targeting the MGBA. Consequently, advancements in canine epilepsy research have the potential to benefit both veterinary and human medicine. In this work, we investigated the role of the MGBA in canine IE through integrative intestinal microbiome and metabolome comparison of healthy to dogs with IE using, respectively, 16S rRNA sequencing and ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS). These insights could further clarify the role of MGBA in IE, thereby paving the way for novel management opportunities that could contribute to improved seizure control and quality of life in dogs and humans. RESULTS 1. Clinical characteristics of the dogs The clinical characteristics of the study population were described previously 16 . Briefly, we enrolled 39 healthy and 49 dogs diagnosed with IE, in accordance with the International Veterinary Epilepsy Taskforce guidelines 17 , as Tier level I (n = 36) or Tier level II (n = 13). Among the recruited dogs diagnosed with IE, 22 dogs fulfilled the criteria for mild phenotype (MP), and the remaining 27 dogs were categorized as drug-resistant (DR). The most common breeds were Border Collie (n = 17), Crossbred (n = 6), Cane Corso (n = 5) and Golden Retriever (n = 5). Among the 88 dogs, 33 were female (23 castrated), and 55 were male (25 castrated), with a mean age of 4.7 ± 2.2 years and a mean body weight of 26.3 ± 12.8 kg (range 4.4 – 61.0 kg) at the start of the study. In total, 64 dogs were adults (30/39 healthy; 17/22 MP; 17/27 DR), 15 dogs were seniors (6/39 healthy; 5/22 MP; 4/27 DR), and 9 dogs were geriatric (3/39 healthy; 0/22 MP; 6/27 DR). No significant differences in the abovementioned clinical characteristics were detected (Supplementary Tables S1-S4). The mean body condition score (BCS) was 5.23 ± 0.99, with a significantly higher BCS found in DR IE ( P = 0.003), but not in MP dogs, than in healthy dogs. In the three months preceding sample collection, dogs with IE experienced a seizure frequency between 0 and 10 seizures per month; the mean seizure frequency (MSF) for DR dogs was 2.9 ± 2.2, and that for MP dogs 0.2 ± 0.3 seizures/month. The median (interquartile range) time between the last epileptic seizure and fecal sampling was significantly longer ( P < 0.001) for MP, i.e., 118 (83) days than for DR dogs, i.e., 7 (16) days. The age of epileptic seizure onset for dogs with IE was 2.5 ± 1.5 years, whereas no significant difference was observed between MP and DR dogs (Supplementary Tables S1-4). Cluster seizures and status epilepticus were present in 30 dogs, i.e., 61.2% (19 DR and 11 MP), and 13 dogs, i.e., 26.5% (8 DR and 5 MP), respectively. Furthermore, all the IE dogs except 3 (MP) received ASM. Among these dogs, 27 dogs received poly- and 19 monotherapy. Phenobarbital, potassium bromide and/or levetiracetam were used in 37 (23 DR and 14 MP), 22 (15 DR and 7 MP) and 11 (7 DR and 4 MP) dogs, respectively. Imepitoin was used in 5 dogs (2 DR and 3 MP), whereas clonazepam and CBD-oil were each used in one DR dog as part of their seizure management. Seizure characteristics and type of ASM were not significantly different between MP and DR dogs. 2. Targeted metabolite profiling Among the 148 targeted fecal metabolites that met the inclusion criteria (Supplementary Table S5), six were significantly altered between healthy, DR and MP IE dogs (Fig. 1). Inosine was significantly lower in the feces of DR dogs as compared to healthy ( P = 0.027) and MP IE dogs ( P = 0.009). Serotonin was significantly higher in the feces of MP dogs as compared to healthy ( P = 0.034) and DR dogs ( P = 0.012). Both fecal histamine and 1-methylhistamine were significantly higher for DR vs. healthy dogs ( P = 0.022 and P = 0.024, respectively). Indole-3-carboxylic acid was significantly lower in the feces of MP ( P = 0.036) and DR ( P = 0.012) as compared to healthy dogs. Finally, fecal 3-4-dimethoxyphenylacetic acid was significantly lower for MP vs. healthy dogs ( P = 0.020). Figure 1: Schematic overview of the significantly altered fecal metabolites in IE compared to healthy dogs . Boxplots represent the iQC normalized peak areas of each metabolite per group. Significant comparisons ( P < 0.05) are indicated with ‘*’. His: histidine, Trp: tryptophan, HDC: histidine decarboxylase, PLP: pyridoxal-5-phosphate, HNMT: histamine-N-methyl transferase, DR: drug-resistant (red), MP: mild phenotype (yellow), healthy (green), SD: standard deviation, 3,4 dimethoxyphenylAA: 3,4 dimethoxyphenylacetic acid. This figure was created by the authors using biorender.com. Although the level of fecal indole was not significantly different between the healthy, MP and DR groups, a significant positive association with MSF was found via linear regression (Table 1). Additionally, the linear regression model revealed three metabolites positively associated with MSF, i.e., 7-ketodeoxycholate, cholic acid and trans-4-hydroxyproline. Finally, a trend towards positive association with MSF was observed for 6 additional metabolites (Table 1). Table 1 : Results of the generalized linear model “Mean seizure frequency ~ metabolite + body condition score + sex + phenobarbital usage + potassium bromide usage + levetiracetam usage”. Metabolites for which P < 0.10 are presented, whereby significant P -values ( P < 0.05) are indicated in bold. SD = standard deviation. Metabolite Estimate SD P -value 7-Ketodeoxycholate 0.786 0.273 0.007 Indole -0.792 0.329 0.021 Trans-4-Hydroxy-proline 0.812 0.367 0.033 Cholic acid 0.861 0.395 0.035 8-Hydroxyquinoline 0.792 0.396 0.053 Tryptophan 0.659 0.343 0.062 N-Acetyl-methionine 0.645 0.366 0.086 D/β-Alanine 0.694 0.399 0.090 Carnitine 0.523 0.302 0.091 N6,N6,N6 Trimethyl-lysine 0.492 0.292 0.099 3. Fecal metabolic fingerprints Untargeted analysis generated 3690 features, of which 2220 in the positive and 1470 in the negative ion mode. The discriminative power of the fecal metabolome was examined by building OPLS-DA models for the different pairwise comparisons, resulting in three OPLS-DA models being compliant with the set validation criteria (Fig. 2), i.e., healthy vs . IE, healthy vs . DR and healthy vs . MP. From the validated OPLS-DA models, 15 features with a VIP > 1, S-plot correlations |p(corr)| > 0.4, and jackknife confidence intervals not across zero could be retained, thus consistent with good discriminative quality. Of these, 3 features discriminated MP, and 13 features discriminated the DR fecal metabolome from that of healthy dogs. Among these features, one unidentified feature discriminated both MP and DR patients from healthy dogs, and four features could be putatively identified using the Chemspider database (MSI level II 18 ). Putative 4-hydroxyphenobarbital 19 , which should indeed only be present in the feces of dogs receiving phenobarbital, 1-beta-hydroxycholic acid 20 , a bile acid, and Boc-Asn-OH 21 , a derivative of the amino acid asparagine, were higher in DR patients vs. healthy controls. Putative 2-(2-carboxyethyl)-4-methyl-5-pentyl-3-furoic acid 22 , a type of heterocyclic fatty acid, was lower in the feces of DR vs. healthy dogs. Figure 2 : OPLS-DA score plots of the fecal metabolic fingerprints, with each dot representing an individual dog. Untargeted data were iQC normalized, log transformed, and Pareto scaled prior to plotting. a) OPLS-DA of HC vs . IE b) OPLS-DA of HC vs . MP and c) OPLS-DA of HC vs . DR. The validation parameters of each model are displayed at the bottom of the respective plot. Furthermore, a good permutation plot (n = 100) was obtained for a, b and c. HC: healthy (green); IE: idiopathic epilepsy (orange), i.e., MP and DR; MP: mild phenotype (yellow); DR: drug-resistant (red). Pathway enrichment analysis (Fig. 3) revealed involvement of vitamin B6 metabolism ( P = 0.003), primary bile acid biosynthesis ( P = 0.017) and taurine and hypotaurine metabolism ( P = 0.035). Within these, eicosapentaenoic acid was putatively identified (MSI level II 18 ) and increased fecal levels in IE compared to healthy dogs were observed. Within the vitamin B6 pathway, the algorithm putatively identified pyridoxine and pyridoxamine. We could however not confirm this identification using analytical standards, and therefore, this result was discarded. The accompanying chromatograms are displayed in Supplementary fig. S1. Figure 3: Pathway enrichment plots of positively (a) and negatively (b) ionized untargeted metabolic features whereby all matched pathways are presented as circles. The color and size of each circle corresponds to its transformed combined P -value. Large (r) and dark (er) red circles are considered the most perturbed pathways. P -values for the GSEA and mummichog algorithms are displayed on the x- and y-axes, respectively. BA: bile acid; PLP: pyridoxal-5-phosphate, i.e., vitamin B6; UFA: unsaturated fatty acids; cys: cysteine; met: methionine; ala: alanine; asp: aspartate; glu: glutamate. This figure was created by the authors using the functional analysis module in MetaboAnalyst 6.0 84 . 4. Fecal microbiome screening Alpha diversity was not significantly different between groups (Chao1 P = 0.57, Shannon P = 0.63). Beta diversity indices were significantly different between healthy and MP dogs (Jaccard P = 0.01, unweighted Unifrac P = 0.02) and between healthy and DR dogs (unweighted Unifrac P = 0.04). However, when relative abundance and phylogenetic distance were considered via the weighted UniFrac index, no significant differences remained (healthy vs. DR P = 0.65; healthy vs. MP P = 0.38; MP vs. DR P = 1.00). The microbial composition differed between IE and healthy dogs, when evaluating relative abundancies (Fig. 4). At the genus level, an increase in fecal Clostridium sensu stricto 1 ( P = 0.001; L2FC = 3.26) and Escherichia-Shigella ( P = 0.021; L2FC = 3.55) was detected in DR compared to healthy dogs. Moreover, a decrease in fecal Succinivibrio ( P = 0.028; L2FC = -4.41) and Phascolarcobacterium ( P = 0.042; L2FC = -2.39) was detected in MP compared to healthy dogs. When the amplicon sequence variant (ASV) level was examined, no significant differences between DR and healthy dogs remained. However, in the feces of MP dogs, one bacterial species was increased, i.e., Blautia hominis ( P = 0.012; L2FC = -1.44), and three species were decreased, i.e., Phascolarcobacterium succinatutens ( P = 0.012; L2FC = 5.11), Segatella copri DSM 18205 (i.e., Prevotella 9, P = 0.016; L2FC = 3.70) and Succinivibrio spp. ( P = 0.016; L2FC = 4.47), compared to healthy dogs. For the latter, no identification at the species level was possible. Figure 4: Differentially abundant ASVs (a) and genera (b) in dogs with idiopathic epilepsy compared to healthy dogs. (a) Heatmap displaying the differentially abundant bacteria at the ASV level. (b) Boxplots representing the relative abundances of the differentially abundant genera for drug-resistant (DR) and mild phenotype (MP) dogs compared with healthy controls (HC). This figure was created by the authors using the R DeSeq2 90 and ggplot2 (v.3.4.4) packages. 5. Correlations between metabolites and microbes Spearman correlation analysis revealed 677 significantly correlated metabolite‒ASV pairs, whereby 3 pairs were associated with a | ρ | > 0.4. Benzoic acid was positively correlated with both ASV 161, i.e., Clostridium hiranonis ( P < 0.001; ρ = 0.42, and ASV 210, i.e., Bacteroides ( P < 0.001; ρ = 0.45). Creatine was negatively correlated with ASV 66, i.e., Segatella copri DSM 18205 ( P | ρ | > 0.2 (Supplementary table S6). DISCUSSION Our study revealed alterations in fecal metabolome and microbial composition in IE compared with healthy dogs, while the nutritional background was standardized. These findings support a role for the MGBA in the pathophysiology of canine IE, and provide insights into the underlying mechanisms involved in this bidirectional communication. 1. Metabolic alterations in feces of dogs with IE related to inflammation. The levels of both histamine and 1-methylhistamine were higher in the feces of DR dogs than in those of healthy dogs. In the GI system, histamine is typically derived from L-histidine by histidine decarboxylase (HDC) and is degraded by histamine-N-methyl transferase (HNMT) in the cytosol or by membrane-bound HNMT to 1-methylhistamine 23 . Histamine can either be produced by immune cells in the periphery of the host, such as mast cells or dendritic cells 24 or by certain types of bacteria 25 . Under normal physiological conditions, mast cells 26 and dendritic cells 27 can cross the blood-brain barrier (BBB), linking host-produced histamine in the periphery to histamine in the brain. In mammals, HDC is an enzyme dependent on pyridoxal-5-phosphate (PLP), i.e. the active form of vitamin B6 28 , whereas bacterial HDC can use either pyruvoyl or PLP as a coenzyme 25 . Interestingly, the authors recently described a decreased PLP plasma concentration in the same study population of dogs with IE compared with healthy dogs, despite a standardized nutritional background 16 .The observed increase in fecal histamine/1-methylhistamine could be linked to the decrease of plasma PLP in dogs with IE. However, this decrease in PLP was observed in both MP and DR dogs, whereas the levels of fecal histamine and 1-methylhistamine were significantly increased in DR dogs only. The increase in Clostridium sensu stricto 1 and Escherichia-Shigella in dogs with DR might thus play a role in this, as these bacteria have the genetic potential to use pyruvoyl-dependent HDC 25 . Moreover, histamine sensing in Escherichia coli (E.Coli) , a member of the Escherichia-Shigella genus, increases the bacterial catabolism of short-chain fatty acids (SCFAs), thereby interfering with the regulatory role of SCFAs in the intestine 29 and promoting a proinflammatory environment. On the other hand, the increased fecal histamine could indicate decreased GI barrier integrity, leading to leakage of histamine. Hereby, the timing between last seizure and sampling could explain the difference between DR and MP, as acute effects on GI barrier integrity are expected, similar to what is seen after stroke in humans 30 . Regardless of the source, intestinal histamine contributes to peripheral inflammation via histamine H 2 receptors (H 2 Rs), leading to BBB disruption and the recruitment of other immune cells, ultimately connecting the innate immune response in the intestines to the brain 31 . In the central nervous system however, a complex interaction between histamine, neural excitability and epilepsy exists, whereby the effect on seizure propagation in different animal models is dependent on the location and type of receptor (H 1,2,3 or H 4 R) 32 . Several animal studies have shown that histamine decreases in different brain regions during focal and generalized seizures. Therefore, a protective effect of high brain histamine levels was suspected, although it is unclear how brain histamine levels flux during the different stages of the disease epilepsy 32 . The increased fecal histamine observed in DR dogs in our study is however unlikely to be related to central histamine, and an indirect effect on the CNS through peripheral inflammation is hypothesized. Inosine, which was decreased in the feces of DR compared to MP and healthy dogs, is a degradation product of adenosine. Adenosine metabolism increases under stressful conditions such as inflammation, producing more inosine. Inosine in turn acts as a signaling molecule that can modulate the immune system 33 . An increase in blood purines, i.e., inosine, hypoxanthine and xanthine, was correlated with seizure severity and neurodegeneration in mouse models 34 . In people with temporal lobe epilepsy, increased baseline (> 24 h following a seizure event) blood purine levels were found compared to those in controls 34 . Moreover, anti-epileptic properties for inosine have been described in different tonic‒clonic seizure animal models, including mice 35 and zebrafish 36 . Conversely, pro-epileptic properties for uric acid and inosine were found in a rat model of ‘absence seizures’ 37 . The decrease in fecal inosine in DR dogs observed in our study suggests that more inosine is degraded by the GI microbiota or less inosine is excreted. A negative correlation was found between Cl. sensu stricto 1 and hypoxanthine (Supplementary table S6), i.e. an inosine metabolite, which would be consistent with an increased microbial breakdown in DR dogs. On the other hand, if less inosine is excreted, more inosine is potentially metabolized to hypoxanthine, xanthine and uric acid or transported to the brain in dogs with DR IE. This may be linked to the perturbation of the taurine and hypotaurine pathways in IE, detected via pathway enrichment analysis, as taurine can attenuate xanthine oxidase 38 , the enzyme required to transform xanthine into uric acid 39 . Uric acid as such has been linked previously to cytotoxic brain injury and oxidative stress 40 , aspects that might contribute to DR in dogs. 2. Metabolic alterations in feces of dogs with IE related to tryptophan metabolism. An increase in fecal serotonin was observed in MP compared to both DR and healthy dogs. Peripheral serotonin cannot cross the BBB under normal physiological conditions 41 . However, over 90% of the body’s serotonin is produced in the intestines, mainly by enterochromaffin (EC) cells, overflowing to the GI lumen and blood circulation 42 . Thus, the fecal serotonin detected in the current study corresponds to the leftover EC-produced serotonin pool. The EC serotonin pool targets primary afferent neurons in the GI tract, signaling nausea and discomfort from the GI tract to the brain, and regulating peristalsis and secretion in the GI tract 43 . Murine studies have shown that intestinal bacteria play a regulatory role in body serotonin levels 44 . More specifically, E. coli can have the genetic ability to produce serotonin, in addition to PLP, tryptophan and indole 45 , and might therefore be involved in alterations in these metabolites. Previously, anticonvulsive properties and reduced mortality have been associated with higher CNS serotonin levels in humans and mice 46 . However, it is unclear whether the EC serotonin pool could have similar effects mediated by signaling from the GI system to the brain. It has been demonstrated that this signaling pathway involves the afferent fibers of the vagal nerve 47 , which is a common target for neuromodulation in epilepsy in both humans 48 and dogs 49 . Indole, a bacterial degradation product of tryptophan, was negatively associated with the MSF in IE dogs and tryptophan as such tended to be positively associated with MSF. These associations could indicate greater bacterial degradation of tryptophan in dogs with a lower MSF. Thereby, indole enhances the intestinal epithelial barrier function 50 , which might reduce the leakage of inflammatory mediators to the peripheral circulation, and ultimately the CNS. Indole-3-carboxylic acid, another indole metabolite derived from tryptophan, was significantly lower in the feces of IE (both MP and DR) compared to healthy dogs. Simultaneously, higher serotonin levels were detected in MP (i.e. dogs with a lower MSF) than in DR dogs. Moreover, a negative correlation between tryptophan and Segetella Copri and Succinivibrio spp ., both decreased in MP dogs, was found, indicating that both spp. may be involved in the microbial turnover of tryptophan. Ultimately, we hypothesize that dogs with a lower MSF have greater turnover of tryptophan to serotonin and indole 43 , both exerting potential positive effects, i.e. stimulation of the vagal nerve and enhancement of the epithelial barrier, respectively. 3. Fecal metabolic alterations differ between dogs with MP and DR IE. Compared to those in healthy dogs, the metabolic alterations were different for dogs with DR and MP IE, revealing an interaction between seizure frequency, severity or response to ASM and the fecal metabolome/microbiome. This may be cause or consequence, i.e. the fecal metabolome and microbiome in MP IE dogs may have a protective effect, leading to a lower MSF and/or a better response to ASM. Previously, a study revealed that mice receiving fecal microbiota from an epileptic mouse showed an increase in seizure susceptibility compared to recipients of healthy microbiota 51 . Moreover, the presence of systemic inflammatory diseases has the capacity to aggravate epileptogenesis 52 . Therefore, the seizure characteristics in our study might be caused by the different GI metabolic environments. On the other hand, it is possible that peripheral alterations induced by the condition, such as inflammation, are less pronounced in MP compared to DR IE as a consequence of the milder phenotype. Epilepsy as such can increase the BBB permeability 53 , potentially attributing to systemic alterations beyond CNS involvement. Finally, the potential confounding effect of the time between the last epileptic seizure and sampling should be considered. This time interval was significantly lower in DR dogs, with a median time interval of 7 days compared to a median time interval of 118 days in MP dogs. A shorter interval may have resulted in more acute alterations caused by epileptic seizures compared to longer intervals in MP dogs; where no acute effects are presumed. 4. Microbial alterations in feces of dogs with IE. Compared with those of healthy dogs, the feces of dogs with MP and DR presented significantly altered differential abundances of multiple bacterial genera. These alterations were different for each group; however, no significant differences were observed when the fecal microbiome compositions of DR and MP dogs were compared directly. Interestingly, all alterations found in our study, both for MP and DR dogs, were also observed previously in dogs with idiopathic inflammatory bowel disease (IBD), in comparison to healthy dogs 54 . Although alterations in microbial composition differ between dogs and humans 55 , a similar IBD pathophysiology comprising an immune-mediated basis, influenced by genetic and environmental factors, has been proposed 56 . Further similarities with IBD could be substantiated when evaluating the metabolic fingerprint, whereby our study putatively showed altered primary bile acid biosynthesis in dogs with IE. Whereas in dogs with IBD, one of the major metabolic alterations included a decrease in secondary bile acids, i.e., deconjugated primary bile acids formed by the intestinal microbiome 57 . According to a human population-based study, IBD increases the risk for epilepsy, with an adjusted hazard ratio of 1.30 58 . Although there are, to the best of our knowledge, no studies linking IE and IBD in dogs, our fecal metabolome and microbiome findings support a bidirectional link between the CNS and an inflammatory GI environment. Compared to those in healthy dogs, the abundances of the genera Clostridium sensu stricto 1 and Escherichia-Shigella were greater in dogs with DR IE. The latter is in line with microbiome alterations in humans, whereby an increase was observed in adults with poststroke epilepsy 59 , in infants with epilepsy and comorbid diarrhea 60 , in children with focal epilepsy in the pretreatment phase 61 , as well as in an adult epilepsy cohort 62 . Moreover, a shift toward reduced carbohydrate metabolism, linked to an increase in the Escherichia genus, was observed in children with severe epilepsy on a ketogenic diet, raising concerns about the functional microbial alterations caused by this type of diet 63 . However, in IE dogs receiving a specific type of ketogenic diet, i.e., medium chain triglycerides (MCTs), no significant alterations in the genus Escherichia have been noted 64,65 . Interestingly, in the latter of these MCT dog studies, lower levels of the Blautia genus were detected in DR vs. MP dogs at baseline 65 , whereas in our study, Blautia hominis was increased in MP compared to healthy dogs. In the MCT dog study by Pilla and colleagues, a decrease in Blautia spp . compared with the baseline was observed in both the placebo and MCT-diet groups 64 . However, no conclusion could be drawn regarding the reason for this decrease. In humans, Blautia spp . are generally considered to have anti-inflammatory properties 66,67 . A generalized conclusion of effects at the genus level should be avoided but considered at the species or even strain level 68 . In the context of the gut‒brain axis, Blautia hominis was more abundant in an elderly human population not experiencing postoperative delirium (n = 20) compared to elderly people experiencing postoperative delirium (n = 20) 69 , suggesting a positive effect in the context of MGBA communication. Surprisingly, at the ASV phylogenetic level, only significantly different ASVs were found between MP and healthy dogs. Segetella Copri DSM 18205 , whose abundance was decreased in MP dog feces, has been shown to produce proinflammatory cytokines and promote a Th-17-mediated immune response in vitro 70,71 . This further substantiates our hypothesis that MP dogs exhibit fewer proinflammatory characteristics in their intestinal environment than DR dogs. Dogs with MP IE also presented a lower abundance of Phascolarctobacterium succinatutens and Succinivibrio spp., both of which are involved in propionate production in dogs 72 . Propionate, as such, is important in the regulation of hepatic lipid metabolism and satiety in the host 73 . It could be hypothesized that the ASV alterations in MP dogs are therefore potentially related to a positive response to ASM. 5. Study strengths and limitations The strengths of our study are the simultaneous analysis of both fecal metabolomics and microbiomics, providing an in-depth characterization of changes in the GI system of IE compared to healthy dogs. To the best of our knowledge, multi-omics integration at this level has been performed only once in subjects with naturally occurring epilepsy, i.e., children with DR epilepsy 74 . Our study is the first in dogs, as well as the first to include an MP group, as well as standardized nutrition, hence excluding interfering dietary effects. In the microbiome, functional redundancy is typically present, emphasizing the importance of the role for specific bacteria in addition to their phylogenetic composition. Our study attempted to include functional information by combining microbiome and metabolome data. However, complex interactions among the host, intestinal microbiome and metabolites exist, challenging the biological interpretation of the data. In the present study, few meaningful interactions between microbial species and metabolites could be revealed. Therefore, future studies should attempt to expand microbiome analysis by e.g. including functional protein analysis, like PICRUSt 75 . Since all dogs with IE except 3 received ASM at the time of sampling, ASM is considered as an important confounder. Future research should therefore aim to include drug-naïve dogs and evaluate the effects of ASM on the fecal metabolome and microbiome. Furthermore, the time between the last seizure and sampling is another important confounder, especially in the comparison between MP and DR dogs. Future studies should consider multiple sampling timepoints related to the last seizure in dogs with IE to discriminate acute seizure effects from chronic alterations. CONCLUSION Dogs with IE presented an altered fecal metabolic fingerprint and profile, and differences in microbiome composition compared to healthy dogs (on a standardized nutritional background). Overall, the feces of dogs with DR IE presented alterations suggesting a proinflammatory GI environment, i.e. an increase in histamine and 1-methylhistamine, and a decrease in inosine, as well as elevated Escherichia-Shigella and Clostridium sensu stricto 1 . In contrast, the feces of dogs with MP IE revealed increased serotonin and inosine compared to healthy and DR dogs. In addition, Blautia hominis was increased, whereas the genera Succinivibrio and Phascolarctobacterium were decreased. The noted changes have previously been linked to positive GI health effects, including anti-inflammatory properties and enhanced epithelial barrier function. Our study suggests a role for the MGBA in the pathophysiology of canine epilepsy, potentially influencing the response to ASM and/or seizure frequency. Our multi-omics approach also unraveled novel metabolic pathways of interest, including histamine and tryptophan metabolism, which could be further exploited in future targeted research and intervention studies. MATERIALS AND METHODS 1. Study design and subjects The study protocol (Fig. 5), approved by the Ethical Committee of Veterinary Medicine and Bioscience Engineering, Ghent University (EC2020-091), included three groups of client-owned dogs: healthy dogs, MP IE dogs, and DR IE dogs. The inclusion criteria for all dogs included anamnesis, unremarkable general physical and neurological exams, and no abnormalities on blood or urine tests. The BCS was recorded on a 9-point scale, with 4–5 points considered ideal 76 . Figure 5: Study protocol. HC: Healthy controls; MP: mild phenotype idiopathic epilepsy; DR: drug resistant idiopathic epilepsy; UHPLC-HRMS: ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. This figure was created by the authors using biorender.com. For dogs with IE, alterations in liver enzymes (ALT, ALP) and electrolytes (K, Na, Cl) without clinical relevance and related to ASM were retained. No antibiotics were allowed three months prior to sample collection. IE diagnosis followed the International Veterinary Epilepsy Taskforce guidelines, i.e. Tier I (based on signalment, medical history, video evaluation of a seizure and routine blood examination) or II (Tier I + bile acids, MRI and cerebrospinal fluid evaluation) 17 . An epileptic seizure diary for three months prior to the start of the study was needed, allowing the classification of dogs. Within the MP group dogs with ≤1 seizure/ 3 months and no status epilepticus nor cluster seizures, and dogs with a good response to ASM, i.e. >50% seizure reduction post-ASM adjustment, were included. Whereas dogs were categorized as DR if there was failure to achieve >50% seizure reduction despite ≥2 ASMs for ≥2 months 77 . All dogs received an adult maintenance diet (Purina® Proplan® Medium Adult with Optibalance) and treats (Purina® Proplan® Dental Probar) per FEDIAF 2019 guidelines based on maintenance energy requirements (MER). The owners were instructed to adhere strictly to the provided diet for at least 20 days. Freshly voided fecal samples were collected within 15 minutes, frozen, and stored for a maximum of 24 h at home by the owners until cooled transport. After arrival at the research facility, samples were aliquoted for DNA extraction and 16S rRNA sequencing (stored at -20°C), as well as for metabolome analysis (stored at -80°C). Fecal aliquots for metabolome analysis were subjected to 72 h of lyophilization to eliminate microbial activity and facilitate homogenization. Plasma samples from the same study were collected and analyzed, of. which results were published previously 16 . 2. Metabolomics analysis Generic extraction, followed by UHPLC-HRMS analysis of the fecal metabolome, was performed via a validated extraction protocol and analysis method 78 . In-house standard mixtures of 371 metabolites (Supplementary Table S5) were used to validate the operational conditions, together with quality control (QC) samples prepared from a representative pool of fecal sample extracts (n = 50) and a negative control sample, i.e., a blank sample prepared following the extraction protocol. Standard mixtures were injected at the beginning and end of the sequence. QC samples and a negative control sample were injected at the beginning, following every 10 biological samples and at the end of the sequence. Biological samples were analyzed in a randomized order 72 . 3. Microbiomics analysis Bacterial DNA for microbiome analysis was extracted via the QIAamp® PowerFecal Pro DNA extraction kit. One sample could not be included in the microbiome analysis owing to technical issues during DNA extraction (DR; dog 95), resulting in 87 analyzed fecal samples (39 healthy, 26 DR and 22 MP). Positive controls (n = 4; ZymoBIOMICS® Microbial Community Standard) were included to assess the quality of sample preprocessing and sequencing. Bacterial barcoding was conducted through a 2-step amplification process utilizing the primers S-D-Bact-0341-b-S-17 (5′-CCTACGGGNGGCWGCAG-3′) and S-D-Bact-0785-a-A-21 (5′-GACTACHVGGGTATCTAATCC-3′), which amplify the V3-V4 region of the 16S rRNA gene as previously described 79 . The final barcoded libraries were sequenced on two different runs via Illumina MiSeq v3 technology (2×300 bp, paired-end) by Macrogen. 4. Data processing and statistical analysis 4.1. Clinical parameters Clinical parameters are described as proportions (categorical data) or means ± standard deviations. Furthermore, dogs are categorized as adult, senior or geriatric dogs based on their age and body weight, since small dog breeds are known to live longer than large dog breeds 80 . Categorical data were compared using a Pearson Chi-square test. Numerical data were analyzed using one-way ANOVA followed by a post-hoc Tukey’s test for normally distributed data or Kruskal-Wallis rank sum followed by Dunn’s test for non-normally distributed data. IE characteristics included the type of epileptic seizure (generalized tonic clonic seizure (gtcs) or focal seizure) 81 , presence of cluster seizures or status epilepticus in the medical history, age at seizure onset, time between sampling and last seizure, and MSF in the 3 months preceding sample collection. Within the IE dogs, numerical data were compared between MP and DR using an independent two-sided T-test or Mann-Whitney U test. For all statistical tests a P-value < 0.05 was considered significant. Details regarding the clinical parameters of the dogs included in the study can be found in Supplementary Table S1-4 and Verdoodt et al ., 2025 (Epilepsia) 16 , where the same population was used to elucidate plasma metabolome alterations in dogs with IE compared with healthy dogs. 4.2. Metabolomics Both targeted metabolites and untargeted features were normalized via internal QCs (iQCs). After iQC normalization, only metabolites with a coefficient of variance (CV) < 30% in the QCs were retained for further analysis. 4.2.1. Targeted metabolomics For the in-house available metabolite standards, peak areas were obtained via manual integration via Xcalibur TM 4.1 (Thermo Fisher Scientific, USA). Only metabolites with a signal-to-noise ratio > 3 in 90% of the samples were considered. Identification was achieved based on accurate mass ( m/z value, considering both the molecular ion and C 13 -isotope) and retention time relative to that of an external standard (level I identification according to the Metabolomics Standards Initiative (MSI)) 18 . Further data processing was executed via Excel (Microsoft, USA) and R (v 4.2.3) 82 . First, fecal metabolite levels were semi-quantitatively compared between groups, i.e., healthy, IE, IE MP or IE DR, via a univariate approach 83 . Three-group comparisons (healthy vs. MP vs . DR) were performed via one-way ANOVA for normally distributed metabolites or a Kruskal‒Wallis rank sum test for non-normally distributed metabolites. The significance ( P < 0.05) of each pairwise comparison, i.e. healthy vs . DR, healthy vs . MP and DR vs. MP, was then evaluated using a post hoc Tukey (following ANOVA) or Dunn (following Kruskal-Wallis) test. Second, a generalized linear model was built that included only samples from IE dogs to evaluate the influence of known metabolite levels on the MSF. Within this model, age, sex, BCS and the use (yes vs . no) of the most common ASM, i.e., phenobarbital, potassium bromide and levetiracetam, were added as confounders. The results of the model include an estimate, i.e., an estimated change in the MSF for a one-unit change in each respective metabolite, assuming that all confounders are held constant, a standard error associated with this estimate and a P lin value, considered significant if P lin < 0.05 or a trend if 0.05 < P lin < 0.10. Positive estimates indicate higher fecal levels of the metabolite with a higher MSF. 4.2.2. Untargeted metabolomics Untargeted data preprocessing was performed with Compound Discoverer (CD) 3.3 (Thermo Fisher Scientific, USA), combining positive and negative ions. The detected features were characterized by the m/z value (peak intensity threshold of 500.000 a.u., mass tolerance of 5 ppm), retention time (RT; maximum RT-shift of 0.4 min) and peak intensity (minimal signal-to-noise ratio of 3). Data preprocessing included log transformation and Pareto scaling. Further data processing was executed in Simca 17.1 (Umetrics AB, Sweden) and MetaboAnalyst 6.0 84 . In Simca, an unsupervised multivariate PCA-X model (including the QC samples) was built for exploration of inherent sample variance and QC clustering. The sample data (excluding the QC samples) were then modeled via supervised OPLS-DA, whereby 4 pairwise comparisons were made: healthy vs. IE, healthy vs. DR, healthy vs . MP and DR vs . MP. The model parameters R 2 (Y) for fit, Q 2 (Y) for predictivity (both > 0.5), cross-validated analysis of variance (CV-ANOVA, P value < 0.05) and permutation testing (n = 100) were assessed to evaluate model validity. The discriminative quality of features was investigated on the basis of variance importance in projection (VIP) scores > 1, S-plot correlations |p(corr)| > 0.4, and jackknife confidence intervals not across zero. In parallel, pathway enrichment analysis via the Mummichog and GSEA algorithms in MetaboAnalyst 6.0 was performed for each ionization method separately (without additional filtering steps in the MetaboAnalyst environment), and the fecal metabolome of IE (DR and MP) dogs was compared to that of healthy dogs. Putative identification was pursued whenever possible by matching measured m/z values (< 5 ppm difference) to theoretical m/z values and retention times in the Chemspider or in-house database (level 2 identification according to MSI) 18 . 4.2 Microbiomics The demultiplexing of the amplicon dataset and the deletion of the barcodes were carried out by the sequencing provider. All further statistical analyses were performed in R (v 4.2.3) 82 . The raw sequence reads were trimmed, quality filtered and dereplicated via the dada2 package (v 1.24.0) 85 . First, an initial ASV table was constructed, followed by removal of the chimeras via the removeBimeraDenovo function. Second, the taxonomy was assigned via dada2’s naïve Bayesian classifier method on the basis of the Silva database (v 1.38) 86 . A phylogenetic tree was then constructed via the DECIPHER (v 2.24.0) algorithm 87 , after which a neighbor-joining tree was constructed via phangorn (v 2.10.0) 88 . The resulting phylogenetic tree and ASV table were loaded into phyloseq (v 1.38.0) 89 , whereby a minimal sequencing depth of 10 000 reads was achieved. Within the phyloseq package, alpha (Chao1 and Shannon) and beta (Jaccard, unweighted and weighted UniFrac) diversity indices were calculated and statistically compared between groups via PERMANOVA. Furthermore, ASVs whose total abundance was less than 0.01% and whose prevalence was less than 50% within a group were discarded before further analysis. Significantly ( P < 0.05) differentially abundant bacterial taxa were identified at different phylogenetic levels by applying DESeq2 90 to the resulting compositional data, considering the confounders sex, BCS and age category (adult, senior or geriatric). The taxonomy of significantly differentially abundant ASVs was checked by comparing the differentially abundant ASV sequences to multiple taxonomic databases via the Basic Local Alignment Search Tool (BLAST) 91 , whereby a minimal identical percentage of 98% was considered for identification. 4.3 Multi-omics integration The correlation between targeted metabolites and the microbiome was evaluated via Spearman’s correlation test 92 , resulting in a correlation coefficient ρ and a false discovery rate (FDR)-corrected P value. A metabolite‒ASV correlation was considered significant when P 0.4 were retained for biological interpretation. Additionally, significant pairs with differentially abundant ASVs and 0.4 > | ρ | > 0.2 were reported as supplementary information. Declarations ACKNOWLEDGMENTS F.V. (1S71421N) is supported as an SB PhD fellow by the Research Foundation–Flanders (FWO). L.Y.H. (1297623N) is supported by the Research Foundation - Flanders (FWO). This study was financially supported by Nestlé Purina Petcare Europe. The authors want to thank all the laboratory technicians working at the Laboratory of Integrative Metabolomics for their technical assistance during this project. AUTHOR CONTRIBUTIONS F.V. contributed to the conception and design of the study; the acquisition, analysis and interpretation of the data; and the drafting of the manuscript. L.Y.H. and M.H. contributed to the conception and design of the study; acquisition, analysis and interpretation of the data; and critical revision of the manuscript. L.V. and E.G. contributed to the analysis and interpretation of the data and critical revision of the manuscript. L.V.H., F.V.I. and S.F.M.B. contributed to the interpretation of the data and critical revision of the manuscript. All the authors have read and approved the final version of the manuscript. DATA AVAILABILITY Data on the analytical standards and detailed clinical characteristics of the enrolled dogs are provided in the supplementary information. The raw data will be made available via https://www.ebi.ac.uk/metabolights/MTBLS10915. CONFLICT OF INTEREST F.V. is currently working on a doctoral research project, including the current study, regarding the role of the gastrointestinal microbiome and nutrition in canine IE, which is financially supported by Nestlé Purina Petcare Europe. M.H. is a member of the Advisory Board of Nestlé Purina Petcare. M.H. has been paid for several consulting services by a variety of pet food companies. The authors have no other financial or personal relationships with other people or organizations that could inappropriately influence or bias the content of the paper. ETHICAL DECLARATION This research was conducted in compliance with European legislation on animal experimentation (EU directive 2010/63/EU) and the ARRIVE guidelines. The study protocol was approved by the ethical committee of the Faculty of Veterinary Medicine and Bioscience Engineering, Ghent University (EC2020-091). References World Health Organization. EPILEPSY A Public Health Imperative International League Against Epilepsy . (2019). https://www.who.int/about/licensing Andualem, F. et al. Quality of life and associated factors among people with epilepsy in Ethiopia: a systematic review and meta-analysis. BMC Public. Health 24 , (2024). Yadav, J., Singh, P., Dabla, S. & Gupta, R. Psychiatric comorbidity and quality of life in patients with epilepsy on anti-epileptic monotherapy and polytherapy. Tzu Chi Med. J. 34 , 226–231 (2022). Löscher, W., Potschka, H., Sisodiya, S. M. & Vezzani, A. Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol. Rev. 72 , 606–638 (2020). Sayyed, R. Z. & Khan, M. Microbiome-Gut-Brain Axis. Microbiome-Gut-Brain Axis: Implications on Health (Springer Nature Singapore, 2022). 10.1007/978-981-16-1626-6 Chen, S. J. et al. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson’s Disease. J. Parkinsons Dis. 12 , 1219–1230 (2022). Zhou, M. et al. Microbiome and tryptophan metabolomics analysis in adolescent depression: roles of the gut microbiota in the regulation of tryptophan-derived neurotransmitters and behaviors in human and mice. Microbiome 11, (2023). Jemimah, S., Chabib, C. M. M., Hadjileontiadis, L. & AlShehhi, A. Gut microbiome dysbiosis in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis. PLoS One 18 , (2023). Gernone, F., Uva, A., Silvestrino, M., Cavalera, M. A. & Zatelli, A. Role of Gut Microbiota through Gut–Brain Axis in Epileptogenesis: A Systematic Review of Human and Veterinary Medicine. Biology (Basel) . 11 , 1290 (2022). Chong, D., Jones, N. C., Schittenhelm, R. B., Anderson, A. & Casillas-Espinosa, P. M. Multi-omics integration and epilepsy: Towards a better understanding of biological mechanisms. Progress in Neurobiology vol. 227 Preprint at (2023). https://doi.org/10.1016/j.pneurobio.2023.102480 Charalambous, M. et al. Translational veterinary epilepsy: A win-win situation for human and veterinary neurology. Vet. J. 293 , (2023). Löscher, W. Dogs as a Natural Animal Model of Epilepsy. 9, (2022). Vermeulen, R., Schymanski, E. L., Barabási, A. L. & Miller, G. W. The exposome and health: Where chemistry meets biology. Sci. (1979) . 367 , 392–396 (2020). Obeso, D., Zubeldia-Varela, E. & Villaseñor, A. Uncovering the influence of diet and gut microbiota in human serum metabolome. Allergy: Eur. J. Allergy Clin. Immunol. 76 , 2306–2308 (2021). Potschka, H., Fischer, A., Löscher, W. & Volk, H. A. Pathophysiology of drug-resistant canine epilepsy. Vet. J. 296–297, (2023). Verdoodt, F. et al. Plasma metabolome reveals altered oxidative stress, inflammation, and amino acid metabolism in dogs with idiopathic epilepsy. Epilepsia 10.1111/epi.18256 (2025). De Risio, L. et al. International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs. BMC Vet. Res. 11 , 148 (2015). Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3 , 211–221 (2007). Chemspider Hydroxyphenobarbital. (2024). https://www.chemspider.com/Chemical-Structure.9402 . html?rid=059e1bed-43dd-4b1f-9b0e-1d4047b4d172 . Chemspider. 1beta-hydroxycholic acid. (2024). Chemspider & Boc-Asn. (2024). https://www.chemspider.com/Chemical-Structure.74037.html?rid=f685b552-e7b8-46e2-9b28-0efdf459 f 581 Chemspider. 2-(2-Carboxyethyl)-4-methyl-5-pentyl-3-furoic acid. (2024). Barnes, W. G. & Hough, L. B. Membrane-bound histamine N-methyltransferase in mouse brain: Possible role in the synaptic inactivation of neuronal histamine. J. Neurochem . 82 , 1262–1271 (2002). Barcik, W. et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. Allergy: Eur. J. Allergy Clin. Immunol. 74 , 899–909 (2019). Mou, Z., Yang, Y., Hall, A. B. & Jiang, X. The taxonomic distribution of histamine-secreting bacteria in the human gut microbiome. BMC Genom. 22 , (2021). Silverman, A. J., Sutherland, A. K., Wilhelm, M. & Silver, R. Mast Cells Migrate from Blood to Brain. J. Neurosci. 20 , 401–408 (2000). Constant, O. et al. Role of Dendritic Cells in Viral Brain Infections. Frontiers in Immunology vol. 13 Preprint at (2022). https://doi.org/10.3389/fimmu.2022.862053 Moya-Garcia, A. A., Medina, M. Á. & Sánchez-Jiménez, F. Mammalian histidine decarboxylase: From structure to function. BioEssays vol. 27 57–63 Preprint at (2005). https://doi.org/10.1002/bies.20174 Krell, T. et al. Histamine: A bacterial signal molecule. International Journal of Molecular Sciences vol. 22 Preprint at (2021). https://doi.org/10.3390/ijms22126312 Conesa, M. P. B. et al. Stabilizing histamine release in gut mast cells mitigates peripheral and central inflammation after stroke. J. Neuroinflammation 20 , (2023). Blasco, M. P. et al. Age-dependent involvement of gut mast cells and histamine in post-stroke inflammation. J. Neuroinflammation 17 , (2020). Yang, L., Wang, Y. & Chen, Z. Central histaminergic signalling, neural excitability and epilepsy. British Journal of Pharmacology vol. 179 3–22 Preprint at (2022). https://doi.org/10.1111/bph.15692 Nascimento, F. P., Macedo-Júnior, S. J., Lapa-Costa, F. R., Cezar-dos-Santos, F. & Santos, A. R. S. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor? Frontiers in Neuroscience vol. 15 Preprint at (2021). https://doi.org/10.3389/fnins.2021.703783 Beamer, E. et al. Elevated blood purine levels as a biomarker of seizures and epilepsy. Epilepsia 62 , 817–828 (2021). Ganzella, M., Faraco, R. B., Almeida, R. F., Fernandes, V. F. & Souza, D. O. Intracerebroventricular administration of inosine is anticonvulsant against quinolinic acid-induced seizures in mice: An effect independent of benzodiazepine and adenosine receptors. Pharmacol. Biochem. Behav. 100 , 271–274 (2011). Brillatz, T. et al. Zebrafish-based identification of the antiseizure nucleoside inosine from the marine diatom Skeletonema marinoi. PLoS One 13 , (2018). Lakatos, R. K., Dobolyi, Á. & Kovács, Z. Uric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats. Brain Res. 1686 , 1–9 (2018). Baliou, S. et al. Protective role of taurine against oxidative stress (Review). Molecular Medicine Reports vol. 24 Preprint at (2021). https://doi.org/10.3892/mmr.2021.12242 Sekizuka, H. Uric acid, xanthine oxidase, and vascular damage: potential of xanthine oxidoreductase inhibitors to prevent cardiovascular diseases. Hypertension Research vol. 45 772–774 Preprint at (2022). https://doi.org/10.1038/s41440-022-00891-7 Ament, Z., Bevers, M. B., Wolcott, Z., Kimberly, W. T. & Acharjee, A. Uric Acid and Gluconic Acid as Predictors of Hyperglycemia and Cytotoxic Injury after Stroke. Transl Stroke Res. 12 , 293–302 (2021). Agus, A., Planchais, J. & Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell. Host Microbe . 23 , 716–724 (2018). Erspamer, V. PHARMACOLOGY OF INDOLEALKYLAMINES. Pharmacol. Rev. 6 , 425 (1954). Gershon, M. D. & Tack, J. The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. Gastroenterology 132 , 397–414 (2007). Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 , 264–276 (2015). Averina, O. V. et al. Bacterial metabolites of human gut microbiota correlating with depression. Int. J. Mol. Sci. 21 , 1–40 (2020). Petrucci, A. N., Joyal, K. G., Purnell, B. S. & Buchanan, G. F. Serotonin and sudden unexpected death in epilepsy. Exp. Neurol. 325 , 113145 (2020). Blackshaw, L. A. & Grundy, D. Effects of 5-Hydroxytryptamine on Discharge of Vagal Mucosal Afferent Fibres from the Upper Gastrointestinal Tract of the Ferret . J. Auton. Nerv. Syst , 45 (1993). Dibué-Adjei, M., Kamp, M. A. & Vonck, K. 30 years of vagus nerve stimulation trials in epilepsy: Do we need neuromodulation-specific trial designs? Epilepsy Research vol. 153 71–75 Preprint at (2019). https://doi.org/10.1016/j.eplepsyres.2019.02.004 Harcourt-Brown, T. R. & Carter, M. Long-term outcome of epileptic dogs treated with implantable vagus nerve stimulators. J. Vet. Intern. Med. 37 , 2102–2108 (2023). Bansal, T., Alaniz, R. C., Wood, T. K. & Jayaraman, A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc. Natl. Acad. Sci. U S A . 107 , 228–233 (2010). Mengoni, F. et al. Gut microbiota modulates seizure susceptibility. Epilepsia 62 , e153–e157 (2021). Rana, A. & Musto, A. E. The role of inflammation in the development of epilepsy. Journal of Neuroinflammation vol. 15 Preprint at (2018). https://doi.org/10.1186/s12974-018-1192-7 Hanael, E. et al. Blood-brain barrier dysfunction and decreased transcription of tight junction proteins in epileptic dogs. J. Vet. Intern. Med. 10.1111/jvim.17099 (2024). Díaz-Regañón, D. et al. Characterization of the Fecal and Mucosa-Associated Microbiota in Dogs with Chronic Inflammatory Enteropathy. (2023). 10.3390/ani Vázquez-Baeza, Y., Hyde, E. R., Suchodolski, J. S. & Knight, R. Dog and human inflammatory bowel disease rely on overlapping yet distinct dysbiosis networks. Nat. Microbiol. 1 , 16177 (2016). Cerquetella, M. et al. Inflammatory bowel disease in the dog: Differences and similarities with humans. World Journal of Gastroenterology vol. 16 1050–1056 Preprint at (2010). https://doi.org/10.3748/wjg.v16.i9.1050 Blake, A. B. et al. Altered microbiota, fecal lactate, and fecal bile acids in dogs with gastrointestinal disease. PLoS One 14 , (2019). Chen, C. H., Lin, C. L. & Kao, C. H. Irritable bowel syndrome increases the risk of epilepsy a population-based study. Med. (United States) . 94 , 1–7 (2015). Wei, D. et al. Identification of disordered profiles of gut microbiota and functional component in stroke and poststroke epilepsy. Brain Behav. 13 , (2023). Liu, T. et al. Altered intestinal microbiota composition with epilepsy and concomitant diarrhea and potential indicator biomarkers in infants. Front. Microbiol. 13 , (2023). Zhou, C. et al. Changes and significance of gut microbiota in children with focal epilepsy before and after treatment. Front. Cell. Infect. Microbiol. 12 , (2022). Cui, G. et al. Gut Microbiome Distinguishes Patients With Epilepsy From Healthy Individuals. Front. Microbiol. 12 , (2022). Lindefeldt, M. et al. The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. NPJ Biofilms Microbiomes 5 , (2019). Pilla, R. et al. The Effects of a Ketogenic Medium-Chain Triglyceride Diet on the Feces in Dogs With Idiopathic Epilepsy. Front. Vet. Sci. 7 , (2020). García-Belenguer, S., Grasa, L., Palacio, J., Moral, J. & Rosado, B. Effect of a Ketogenic Medium Chain Triglyceride-Enriched Diet on the Fecal Microbiota in Canine Idiopathic Epilepsy: A Pilot Study. Vet. Sci. 10 , 245 (2023). Kalyana Chakravarthy, S. et al. Dysbiosis in the Gut Bacterial Microbiome of Patients with Uveitis, an Inflammatory Disease of the Eye. Indian J. Microbiol. 58 , 457–469 (2018). Clarke, S. F. et al. Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge. PLoS One 8 , (2013). Liu, X. et al. Blautia—a new functional genus with potential probiotic properties? Gut Microbes vol. 13 1–21 Preprint at (2021). https://doi.org/10.1080/19490976.2021.1875796 Liu, H. et al. Preoperative Status of Gut Microbiota Predicts Postoperative Delirium in Patients With Gastric Cancer. Front. Psychiatry 13 , (2022). Xiao, X., Singh, A., Giometto, A. & Brito, I. L. Segatella copri strains adopt distinct roles within a single individual’s gut. 10.1101/2024.05.20.595015 Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology vol. 151 363–374 Preprint at (2017). https://doi.org/10.1111/imm.12760 Mackei, M. et al. Altered Intestinal Production of Volatile Fatty Acids in Dogs Triggered by Lactulose and Psyllium Treatment. Vet. Sci. 9 , (2022). Weitkunat, K. et al. Importance of propionate for the repression of hepatic lipogenesis and improvement of insulin sensitivity in high-fat diet-induced obesity. Mol. Nutr. Food Res. 60 , 2611–2621 (2016). Gong, X. et al. Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets. Microb. Pathog . 155 , 104899 (2021). Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38 , 685–688 (2020). Laflamme, D. Developmental and validation of a body condition score system for dogs. Canine Pract. 22 , 10–15 (1997). Potschka, H. et al. International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy. BMC Vet. Res. 11 , 1–13 (2015). De Paepe, E. et al. A validated multi-matrix platform for metabolomic fingerprinting of human urine, feces and plasma using ultra-high performance liquid-chromatography coupled to hybrid orbitrap high-resolution mass spectrometry. Anal. Chim. Acta . 1033 , 108–118 (2018). Goossens, E. et al. Acute Endotoxemia-Induced Respiratory and Intestinal Dysbiosis. Int. J. Mol. Sci. 23 , (2022). Fortney, W. D. Implementing a Successful Senior/Geriatric Health Care Program for Veterinarians, Veterinary Technicians, and Office Managers. Veterinary Clin. North. Am. - Small Anim. Pract. 42 , 823–834 (2012). Berendt, M. et al. International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Vet. Res. 11 , (2015). R Core Team. R: A language and environment for statistical computing. Preprint at (2021). https://www.r-project.org/ https:// github.com/UGent-LIMET/Univariate_analysis Xia, J. & Wishart, D. S. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat. Protoc. 6 , 743–760 (2011). Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods . 13 , 581–583 (2016). Quast, C. et al. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 41 , (2013). Wright, E. S. DECIPHER: Harnessing local sequence context to improve protein multiple sequence alignment. BMC Bioinform. 16 , (2015). Schliep, K. P. phangorn: Phylogenetic analysis in R. Bioinformatics 27, 592–593 (2011). McMurdie, P. J., Holmes, S. & Phyloseq An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS One 8 , (2013). Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15 , (2014). Zhang, Z., Schwartz, S., Wagner, L. & Miller, W. A Greedy Algorithm for Aligning DNA Sequences . JOURNAL OF COMPUTATIONAL BIOLOGY vol. 7 www.liebertpub.com (2000). https:// github.com/UGent-LIMET/Correlation_analysis/tree/main Additional Declarations Competing interest reported. F.V. is currently working on a doctoral research project, including the current study, regarding the role of the gastrointestinal microbiome and nutrition in canine IE, which is financially supported by Nestlé Purina Petcare Europe. J.M. is employed by Nestlé Purina Petcare Europe. M.H. is a member of the Advisory Board of Nestlé Purina Petcare. M.H. has been paid for several consulting services by a variety of pet food companies. The authors have no other financial or personal relationships with other people or organizations that could inappropriately influence or bias the content of the paper. Supplementary Files 2025VerdoodtSciRepSupplementary.pdf Cite Share Download PDF Status: Published Journal Publication published 25 Jul, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 17 Feb, 2025 Editor assigned by journal 17 Feb, 2025 Submission checks completed at journal 04 Feb, 2025 First submitted to journal 03 Feb, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5953419","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":410959037,"identity":"e3536f8d-e4ab-4121-b70e-15490414560d","order_by":0,"name":"Fien Verdoodt","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Fien","middleName":"","lastName":"Verdoodt","suffix":""},{"id":410959038,"identity":"bdd0fd1f-f314-4cc2-8a57-9b65e95e1438","order_by":1,"name":"Myriam Hesta","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Myriam","middleName":"","lastName":"Hesta","suffix":""},{"id":410959039,"identity":"e506176b-8ca4-45ca-a0e2-78dc7286d173","order_by":2,"name":"Evy Goossens","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Evy","middleName":"","lastName":"Goossens","suffix":""},{"id":410959040,"identity":"f034110b-5dea-4123-ab2b-028fb50cd007","order_by":3,"name":"Filip Van Immerseel","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Filip","middleName":"Van","lastName":"Immerseel","suffix":""},{"id":410959041,"identity":"056c2b53-081a-46a4-8a24-9b8e8aa9422f","order_by":4,"name":"Jenifer Molina","email":"","orcid":"","institution":"Nestlé Purina PetCare EUROPE","correspondingAuthor":false,"prefix":"","firstName":"Jenifer","middleName":"","lastName":"Molina","suffix":""},{"id":410959042,"identity":"bdf3d561-cd93-4dd9-bfbb-639653835f96","order_by":5,"name":"Luc Van Ham","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Luc","middleName":"Van","lastName":"Ham","suffix":""},{"id":410959043,"identity":"36f06bd9-4464-4851-8df1-c772e53b9d92","order_by":6,"name":"Lynn Vanhaecke","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Lynn","middleName":"","lastName":"Vanhaecke","suffix":""},{"id":410959045,"identity":"eeac4d2d-acdc-427e-90a2-afef6f2eb4c0","order_by":7,"name":"Lieselot Y. Hemeryck","email":"","orcid":"","institution":"Ghent University","correspondingAuthor":false,"prefix":"","firstName":"Lieselot","middleName":"Y.","lastName":"Hemeryck","suffix":""},{"id":410959050,"identity":"2d3649a4-62c6-45df-ab22-ddc31ed7574a","order_by":8,"name":"Sofie F.M. Bhatti","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+klEQVRIie3PvWrDMBAH8DMCezF0DRTiV5DpUDLkXSwyJxkKIUPrGgzKYuiaqXmF9A1kDi5LyJzR0Bfw6EFDZBtKJznZAtF/0Qf66e4AXFzuMFHmVQpAJ+1B1f2lbyVcMW4IJeAzKLc9GCDAuFmwIyy8igS5Z/qhxdPuq8Sp/Bi/Rplf1bZZCmz70W8jYoBzeXiZSAjira3MeakwBBJZT0jsCfzn0EpmgBpQ7FoykfTZET1EzPjmc0M8+Z7wltgEP5pZCk7ih2a8LE4q3pPYxIWFRJuc1c1ai28sf+tmlUYckarGVqav9bczTYKXDYL/SW967eLi4vIYuQDEQFl1vkcyagAAAABJRU5ErkJggg==","orcid":"","institution":"Ghent University","correspondingAuthor":true,"prefix":"","firstName":"Sofie","middleName":"F.M.","lastName":"Bhatti","suffix":""}],"badges":[],"createdAt":"2025-02-03 19:23:20","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5953419/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5953419/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-025-09919-7","type":"published","date":"2025-07-25T15:57:45+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":75608035,"identity":"54968584-234f-43f5-9fcc-2a515d1c5e5a","added_by":"auto","created_at":"2025-02-06 09:51:19","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":224340,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSchematic overview of the significantly altered fecal metabolites in IE compared to healthy dogs\u003c/strong\u003e. Boxplots represent the iQC normalized peak areas of each metabolite per group. Significant comparisons (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) are indicated with ‘*’. His: histidine, Trp: tryptophan, HDC: histidine decarboxylase, PLP: pyridoxal-5-phosphate, HNMT: histamine-N-methyl transferase, DR: drug-resistant (red), MP: mild phenotype (yellow), healthy (green), SD: standard deviation, 3,4 dimethoxyphenylAA: 3,4 dimethoxyphenylacetic acid. This figure was created by the authors using biorender.com.\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/530da868d1aa014fdac7931f.png"},{"id":75608037,"identity":"d5dddf71-a9d7-4e50-be8f-fb6fc73e39c8","added_by":"auto","created_at":"2025-02-06 09:51:19","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":146426,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eOPLS-DA score plots of the fecal metabolic fingerprints, with each dot representing an individual dog.\u003c/strong\u003e Untargeted data were iQC normalized, log transformed, and Pareto scaled prior to plotting. a) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. IE b) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. MP and c) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. DR. The validation parameters of each model are displayed at the bottom of the respective plot. Furthermore, a good permutation plot (n = 100) was obtained for a, b and c. HC: healthy (green); IE: idiopathic epilepsy (orange), i.e., MP and DR; MP: mild phenotype (yellow); DR: drug-resistant (red).\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/c966bf9afb696d27b29804a9.png"},{"id":75608040,"identity":"48486179-b4e3-48b5-a507-590cb0b5e8e2","added_by":"auto","created_at":"2025-02-06 09:51:19","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":119175,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePathway enrichment plots of positively (a) and negatively (b) ionized untargeted metabolic features whereby all matched pathways are presented as circles.\u003c/strong\u003e The color and size of each circle corresponds to its transformed combined \u003cem\u003eP\u003c/em\u003e-value. Large (r) and dark (er) red circles are considered the most perturbed pathways. \u003cem\u003eP\u003c/em\u003e-values for the GSEA and mummichog algorithms are displayed on the x- and y-axes, respectively. BA: bile acid; PLP: pyridoxal-5-phosphate, i.e., vitamin B6; UFA: unsaturated fatty acids; cys: cysteine; met: methionine; ala: alanine; asp: aspartate; glu: glutamate. This figure was created by the authors using the functional analysis module in MetaboAnalyst 6.0 .\u003c/p\u003e\n\u003cp\u003e84\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/78774381774627f70326aff1.png"},{"id":75609523,"identity":"9f94aa05-2374-4597-8b7c-dda723eebdfe","added_by":"auto","created_at":"2025-02-06 09:59:19","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":138175,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDifferentially abundant ASVs (a) and genera (b) in dogs with idiopathic epilepsy compared to healthy dogs. \u003c/strong\u003e(a) Heatmap displaying the differentially abundant bacteria at the ASV level. (b) Boxplots representing the relative abundances of the differentially abundant genera for drug-resistant (DR) and mild phenotype (MP) dogs compared with healthy controls (HC). This figure was created by the authors using the R DeSeq2 and ggplot2 (v.3.4.4) packages.\u003c/p\u003e\n\u003cp\u003e90\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/2891da41942321e9baac0707.png"},{"id":75609525,"identity":"a901b35c-09df-4ebe-8327-ab62e469fe9d","added_by":"auto","created_at":"2025-02-06 09:59:19","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":83915,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStudy protocol.\u003c/strong\u003e HC: Healthy controls; MP: mild phenotype idiopathic epilepsy; DR: drug resistant idiopathic epilepsy; UHPLC-HRMS: ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. This figure was created by the authors using biorender.com.\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/30f68af58289d95f3984def6.png"},{"id":88508973,"identity":"4f24ec0b-b967-45d8-86fd-4e64ffad5cbd","added_by":"auto","created_at":"2025-08-07 07:44:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1831048,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/1d269980-e999-4236-9f15-7820dd30d514.pdf"},{"id":75608038,"identity":"ae1085c5-1efb-4f1c-ba47-b06f5d2c402e","added_by":"auto","created_at":"2025-02-06 09:51:19","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":886389,"visible":true,"origin":"","legend":"","description":"","filename":"2025VerdoodtSciRepSupplementary.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5953419/v1/0e28f35f13364ec3a41e826d.pdf"}],"financialInterests":"Competing interest reported. F.V. is currently working on a doctoral research project, including the current study, regarding the role of the gastrointestinal microbiome and nutrition in canine IE, which is financially supported by Nestlé Purina Petcare Europe. J.M. is employed by Nestlé Purina Petcare Europe. M.H. is a member of the Advisory Board of Nestlé Purina Petcare. M.H. has been paid for several consulting services by a variety of pet food companies. The authors have no other financial or personal relationships with other people or organizations that could inappropriately influence or bias the content of the paper.","formattedTitle":"The fecal metabolome and microbiome are altered in dogs with idiopathic epilepsy compared to healthy dogs","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eEpilepsy is a chronic non-communicable disease of the brain that is characterized by recurring spontaneous seizures. It affects 50\u0026nbsp;million people worldwide \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e, with a detrimental effect on the quality of life of people with the disease as well as their families \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Moreover, one-third of people with epilepsy cannot achieve a life without seizures with the currently available antiseizure medication (ASM) \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. In 32% of cases, the etiology of human epilepsy remains unknown \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e, highlighting important knowledge gaps. Further exploration of mechanisms involved in epilepsy, such as e.g. the microbiota‒gut‒brain axis (MGBA), is therefore needed.\u003c/p\u003e \u003cp\u003eThe MGBA comprises complex bidirectional communication between the gastrointestinal (GI) system and central nervous system (CNS) via neuroanatomical pathways, endocrine, immune and metabolic signaling \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. The importance and effect of the bidirectional connection between the intestinal microbiome and brain health has been documented for e.g. Parkinson\u0026rsquo;s disease \u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e, major depression \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e and Alzheimer\u0026rsquo;s disease \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. As such, the MGBA is an interesting and very promising target for improving brain health in individuals where brain function is hampered, such as those with epilepsy. In epilepsy specifically, research on the MGBA has focused on inflammatory signaling and neuroinflammation \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Other pathways such as neurotransmitter and amino acid metabolism are however also likely involved in the MGBA communication in epilepsy. These pathways can be studied by applying holistic omics approaches. By concurrently analyzing microbial composition, i.e. through microbiomics, and the resulting metabolic outputs, i.e. through metabolomics, an integrative approach enabling a multi-layered view of the biochemical environment within the GI system can be obtained, revealing functional insights that surpass those achieved through single-omics studies \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eCanine idiopathic epilepsy (IE) serves as an established animal model for human epilepsy types with genetic and unknown etiologies \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Canine and human epilepsy share similar electrophysiological and pharmacological characteristics \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e, in addition to clinical features such as status epilepticus and behavioral comorbidities \u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Pets moreover often share their living environment with humans, leading to a largely similar exposome, i.e. the whole of nongenetic environmental drivers for health and disease \u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. The nutritional management of pets offers a significant advantage, being that a standardized nutritional background can be easily implemented. Dogs can be fed an identical qualitatively balanced kibble diet that meets their nutritional requirements, thus ruling out nutritional inadequacies. This is particularly important in omics studies, where nutrition is a major and highly variable, environmental determinant \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. As in humans with epilepsy, one third of dogs with IE are inadequately managed with ASM \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, indicating the need for novel approaches such as targeting the MGBA. Consequently, advancements in canine epilepsy research have the potential to benefit both veterinary and human medicine.\u003c/p\u003e \u003cp\u003eIn this work, we investigated the role of the MGBA in canine IE through integrative intestinal microbiome and metabolome comparison of healthy to dogs with IE using, respectively, 16S rRNA sequencing and ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS). These insights could further clarify the role of MGBA in IE, thereby paving the way for novel management opportunities that could contribute to improved seizure control and quality of life in dogs and humans.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003e1. \u0026nbsp; Clinical characteristics of the dogs\u003c/p\u003e\n\u003cp\u003eThe clinical characteristics of the study population were described previously \u003csup\u003e16\u003c/sup\u003e . Briefly, we enrolled 39 healthy and 49 dogs diagnosed with IE, in accordance with the International Veterinary Epilepsy Taskforce guidelines \u003csup\u003e17\u003c/sup\u003e, as Tier level I (n = 36) or Tier level II (n = 13). Among the recruited dogs diagnosed with IE, 22 dogs fulfilled the criteria for mild phenotype (MP), and the remaining 27 dogs were categorized as drug-resistant (DR). The most common breeds were Border Collie (n = 17), Crossbred (n = 6), Cane Corso (n = 5) and Golden Retriever (n = 5). Among the 88 dogs, 33 were female (23 castrated), and 55 were male (25 castrated), with a mean age of 4.7 \u0026plusmn; 2.2 years and a mean body weight of 26.3 \u0026plusmn; 12.8 kg (range 4.4 \u0026ndash; 61.0 kg) at the start of the study. In total, 64 dogs were adults (30/39 healthy; 17/22 MP; 17/27 DR), 15 dogs were seniors (6/39 healthy; 5/22 MP; 4/27 DR), and 9 dogs were geriatric (3/39 healthy; 0/22 MP; 6/27 DR). No significant differences in the abovementioned clinical characteristics were detected (Supplementary Tables S1-S4). The mean body condition score (BCS) was 5.23 \u0026plusmn; 0.99, with a significantly higher BCS found in DR IE (\u003cem\u003eP\u003c/em\u003e = 0.003), but not in MP dogs, than in healthy dogs.\u003c/p\u003e\n\u003cp\u003eIn the three months preceding sample collection, dogs with IE experienced a seizure frequency between 0 and 10 seizures per month; the mean seizure frequency (MSF) for DR dogs was 2.9 \u0026plusmn; 2.2, and that for MP dogs 0.2 \u0026plusmn; 0.3 seizures/month. The median (interquartile range) time between the last epileptic seizure and fecal sampling was significantly longer (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001) for MP, i.e., 118 (83) days than for DR dogs, i.e., 7 (16) days. The age of epileptic seizure onset for dogs with IE was 2.5 \u0026plusmn; 1.5 years, whereas no significant difference was observed between MP and DR dogs (Supplementary Tables S1-4). Cluster seizures and status epilepticus were present in 30 dogs, i.e., 61.2% (19 DR and 11 MP), and 13 dogs, i.e., 26.5% (8 DR and 5 MP), respectively. Furthermore, all the IE dogs except 3 (MP) received ASM. Among these dogs, 27 dogs received poly- and 19 monotherapy. Phenobarbital, potassium bromide and/or levetiracetam were used in 37 (23 DR and 14 MP), 22 (15 DR and 7 MP) and 11 (7 DR and 4 MP) dogs, respectively. Imepitoin was used in 5 dogs (2 DR and 3 MP), whereas clonazepam and CBD-oil were each used in one DR dog as part of their seizure management. Seizure characteristics and type of ASM were not significantly different between MP and DR dogs.\u003c/p\u003e\n\u003cp\u003e2. \u0026nbsp; Targeted metabolite profiling\u003c/p\u003e\n\u003cp\u003eAmong the 148 targeted fecal metabolites that met the inclusion criteria (Supplementary Table S5), six were significantly altered between healthy, DR and MP IE dogs (Fig. 1). Inosine was significantly lower in the feces of DR dogs as compared to healthy (\u003cem\u003eP\u003c/em\u003e = 0.027) and MP IE dogs (\u003cem\u003eP\u003c/em\u003e = 0.009). Serotonin was significantly higher in the feces of MP dogs as compared to healthy (\u003cem\u003eP\u003c/em\u003e = 0.034) and DR dogs (\u003cem\u003eP\u003c/em\u003e = 0.012). Both fecal histamine and 1-methylhistamine were significantly higher for DR \u003cem\u003evs.\u003c/em\u003e healthy dogs (\u003cem\u003eP\u003c/em\u003e = 0.022 and \u003cem\u003eP\u003c/em\u003e = 0.024, respectively). Indole-3-carboxylic acid was significantly lower in the feces of MP (\u003cem\u003eP\u003c/em\u003e = 0.036) and DR (\u003cem\u003eP\u003c/em\u003e = 0.012) as compared to healthy dogs. Finally, fecal 3-4-dimethoxyphenylacetic acid was significantly lower for MP \u003cem\u003evs.\u003c/em\u003e healthy dogs (\u003cem\u003eP\u003c/em\u003e = 0.020).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 1:\u003c/strong\u003e \u003cstrong\u003eSchematic overview of the significantly altered fecal metabolites in IE compared to healthy dogs\u003c/strong\u003e. Boxplots represent the iQC normalized peak areas of each metabolite per group. Significant comparisons (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) are indicated with \u0026lsquo;*\u0026rsquo;. His: histidine, Trp: tryptophan, HDC: histidine decarboxylase, PLP: pyridoxal-5-phosphate, HNMT: histamine-N-methyl transferase, DR: drug-resistant (red), MP: mild phenotype (yellow), healthy (green), SD: standard deviation, 3,4 dimethoxyphenylAA: 3,4 dimethoxyphenylacetic acid. This figure was created by the authors using biorender.com.\u003c/p\u003e\n\u003cp\u003eAlthough the level of fecal indole was not significantly different between the healthy, MP and DR groups, a significant positive association with MSF was found via linear regression (Table 1). Additionally, the linear regression model revealed three metabolites positively associated with MSF, i.e., 7-ketodeoxycholate, cholic acid and trans-4-hydroxyproline. Finally, a trend towards positive association with MSF was observed for 6 additional metabolites (Table 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1\u003c/strong\u003e: Results of the generalized linear model \u0026ldquo;Mean seizure frequency ~ metabolite + body condition score + sex + phenobarbital usage + potassium bromide usage + levetiracetam usage\u0026rdquo;. Metabolites for which \u003cem\u003eP\u003c/em\u003e \u0026lt; 0.10 are presented, whereby significant \u003cem\u003eP\u003c/em\u003e-values (\u003cem\u003eP\u0026nbsp;\u003c/em\u003e\u0026lt; 0.05) are indicated in bold. SD = standard deviation.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"403\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMetabolite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eEstimate\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eP\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003e7-Ketodeoxycholate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.786\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.273\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eIndole\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e-0.792\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.329\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.021\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eTrans-4-Hydroxy-proline\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.812\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.367\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.033\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eCholic acid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.861\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.395\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.035\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003e8-Hydroxyquinoline\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.792\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.396\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.053\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eTryptophan\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.659\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.343\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.062\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eN-Acetyl-methionine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.645\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.366\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.086\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eD/\u0026beta;-Alanine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.694\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.399\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.090\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eCarnitine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.523\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.302\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.091\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 44.4169%;\"\u003e\n \u003cp\u003eN6,N6,N6 Trimethyl-lysine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 17.866%;\"\u003e\n \u003cp\u003e0.492\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.292\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0.099\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e3. \u0026nbsp; \u0026nbsp;Fecal metabolic fingerprints\u003c/p\u003e\n\u003cp\u003eUntargeted analysis generated 3690 features, of which 2220 in the positive and 1470 in the negative ion mode. The discriminative power of the fecal metabolome was examined by building OPLS-DA models for the different pairwise comparisons, resulting in three OPLS-DA models being compliant with the set validation criteria (Fig. 2), i.e., healthy \u003cem\u003evs\u003c/em\u003e. IE, healthy \u003cem\u003evs\u003c/em\u003e. DR and healthy \u003cem\u003evs\u003c/em\u003e. MP. From the validated OPLS-DA models, 15 features with a VIP \u0026gt; 1, S-plot correlations |p(corr)| \u0026gt; 0.4, and jackknife confidence intervals not across zero could be retained, thus consistent with good discriminative quality. Of these, 3 features discriminated MP, and 13 features discriminated the DR fecal metabolome from that of healthy dogs. Among these features, one unidentified feature discriminated both MP and DR patients from healthy dogs, and four features could be putatively identified using the Chemspider database (MSI level II \u003csup\u003e18\u003c/sup\u003e). Putative 4-hydroxyphenobarbital \u003csup\u003e19\u003c/sup\u003e, which should indeed only be present in the feces of dogs receiving phenobarbital, 1-beta-hydroxycholic acid \u003csup\u003e20\u003c/sup\u003e, a bile acid, and Boc-Asn-OH \u003csup\u003e21\u003c/sup\u003e, a derivative of the amino acid asparagine, were higher in DR patients \u003cem\u003evs.\u003c/em\u003e healthy controls. Putative 2-(2-carboxyethyl)-4-methyl-5-pentyl-3-furoic acid \u003csup\u003e22\u003c/sup\u003e, a type of heterocyclic fatty acid, was lower in the feces of DR \u003cem\u003evs.\u003c/em\u003e healthy dogs.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 2\u003c/strong\u003e: \u003cstrong\u003eOPLS-DA score plots of the fecal metabolic fingerprints, with each dot representing an individual dog.\u003c/strong\u003e Untargeted data were iQC normalized, log transformed, and Pareto scaled prior to plotting. a) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. IE b) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. MP and c) OPLS-DA of HC \u003cem\u003evs\u003c/em\u003e. DR. The validation parameters of each model are displayed at the bottom of the respective plot. Furthermore, a good permutation plot (n = 100) was obtained for a, b and c. HC: healthy (green); IE: idiopathic epilepsy (orange), i.e., MP and DR; MP: mild phenotype (yellow); DR: drug-resistant (red).\u003c/p\u003e\n\u003cp\u003ePathway enrichment analysis (Fig. 3) revealed involvement of vitamin B6 metabolism (\u003cem\u003eP\u0026nbsp;\u003c/em\u003e= 0.003), primary bile acid biosynthesis (\u003cem\u003eP\u0026nbsp;\u003c/em\u003e= 0.017) and taurine and hypotaurine metabolism (\u003cem\u003eP\u003c/em\u003e = 0.035). Within these, eicosapentaenoic acid was putatively identified (MSI level II \u003csup\u003e18\u003c/sup\u003e) and increased fecal levels in IE compared to healthy dogs were observed. Within the vitamin B6 pathway, the algorithm putatively identified pyridoxine and pyridoxamine. We could however not confirm this identification using analytical standards, and therefore, this result was discarded. The accompanying chromatograms are displayed in Supplementary fig. S1.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 3:\u003c/strong\u003e \u003cstrong\u003ePathway enrichment plots of positively (a) and negatively (b) ionized untargeted metabolic features whereby all matched pathways are presented as circles.\u003c/strong\u003e The color and size of each circle corresponds to its transformed combined \u003cem\u003eP\u003c/em\u003e-value. Large (r) and dark (er) red circles are considered the most perturbed pathways. \u003cem\u003eP\u003c/em\u003e-values for the GSEA and mummichog algorithms are displayed on the x- and y-axes, respectively. BA: bile acid; PLP: pyridoxal-5-phosphate, i.e., vitamin B6; UFA: unsaturated fatty acids; cys: cysteine; met: methionine; ala: alanine; asp: aspartate; glu: glutamate. This figure was created by the authors using the functional analysis module in MetaboAnalyst 6.0 \u003csup\u003e84\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e4. \u0026nbsp; Fecal microbiome screening\u003c/p\u003e\n\u003cp\u003eAlpha diversity was not significantly different between groups (Chao1 \u003cem\u003eP\u003c/em\u003e = 0.57, Shannon \u003cem\u003eP\u003c/em\u003e = 0.63). Beta diversity indices were significantly different between healthy and MP dogs (Jaccard \u003cem\u003eP\u0026nbsp;\u003c/em\u003e= 0.01, unweighted Unifrac \u003cem\u003eP\u003c/em\u003e = 0.02) and between healthy and DR dogs (unweighted Unifrac \u003cem\u003eP\u003c/em\u003e = 0.04). However, when relative abundance and phylogenetic distance were considered via the weighted UniFrac index, no significant differences remained (healthy \u003cem\u003evs.\u003c/em\u003e DR \u003cem\u003eP\u003c/em\u003e = 0.65; healthy \u003cem\u003evs.\u003c/em\u003e MP \u003cem\u003eP\u003c/em\u003e = 0.38; MP \u003cem\u003evs.\u003c/em\u003e DR \u003cem\u003eP\u003c/em\u003e = 1.00). The microbial composition differed between IE and healthy dogs, when evaluating relative abundancies (Fig. 4). At the genus level, an increase in fecal \u003cem\u003eClostridium sensu stricto 1\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e = 0.001; L2FC = 3.26) and \u003cem\u003eEscherichia-Shigella\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e = 0.021; L2FC = 3.55) was detected in DR compared to healthy dogs. Moreover, a decrease in fecal \u003cem\u003eSuccinivibrio\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e = 0.028; L2FC = -4.41) and \u003cem\u003ePhascolarcobacterium\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e = 0.042; L2FC = -2.39) was detected in MP compared to healthy dogs. When the amplicon sequence variant (ASV) level was examined, no significant differences between DR and healthy dogs remained. However, in the feces of MP dogs, one bacterial species was increased, i.e., \u003cem\u003eBlautia hominis\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e = 0.012; L2FC = -1.44), and three species were decreased, i.e., \u003cem\u003ePhascolarcobacterium succinatutens\u0026nbsp;\u003c/em\u003e(\u003cem\u003eP\u003c/em\u003e = 0.012; L2FC = 5.11), \u003cem\u003eSegatella copri DSM 18205\u0026nbsp;\u003c/em\u003e(i.e., \u003cem\u003ePrevotella 9,\u003c/em\u003e \u003cem\u003eP\u003c/em\u003e = 0.016; L2FC = 3.70) and \u003cem\u003eSuccinivibrio\u003c/em\u003e spp. (\u003cem\u003eP\u003c/em\u003e = 0.016; L2FC = 4.47), compared to healthy dogs. For the latter, no identification at the species level was possible.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 4: Differentially abundant ASVs (a) and genera (b) in dogs with idiopathic epilepsy compared to healthy dogs.\u0026nbsp;\u003c/strong\u003e(a) Heatmap displaying the differentially abundant bacteria at the ASV level. (b) Boxplots representing the relative abundances of the differentially abundant genera for drug-resistant (DR) and mild phenotype (MP) dogs compared with healthy controls (HC). This figure was created by the authors using the R DeSeq2\u003csup\u003e90\u003c/sup\u003e and ggplot2 (v.3.4.4) packages.\u003c/p\u003e\n\u003cp\u003e5. \u0026nbsp; Correlations between metabolites and microbes\u003c/p\u003e\n\u003cp\u003eSpearman correlation analysis revealed 677 significantly correlated metabolite‒ASV pairs, whereby 3 pairs were associated with a | \u0026rho; | \u0026gt; 0.4. Benzoic acid was positively correlated with both ASV 161, i.e., \u003cem\u003eClostridium hiranonis\u0026nbsp;\u003c/em\u003e(\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001; \u0026rho; = 0.42, and ASV 210, i.e., \u003cem\u003eBacteroides\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001; \u0026rho; = 0.45). Creatine was negatively correlated with ASV 66, i.e., \u003cem\u003eSegatella copri DSM 18205\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001; \u0026rho; = - 0.40). Moreover, for differentially abundant ASVs, an additional 61 metabolite-ASV pairs were identified with 0.4 \u0026gt; | \u0026rho; | \u0026gt; 0.2 (Supplementary table S6).\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eOur study revealed alterations in fecal metabolome and microbial composition in IE compared with healthy dogs, while the nutritional background was standardized. These findings support a role for the MGBA in the pathophysiology of canine IE, and provide insights into the underlying mechanisms involved in this bidirectional communication.\u003c/p\u003e\n\u003cp\u003e1.\u0026nbsp; \u0026nbsp;Metabolic alterations in feces of dogs with IE related to inflammation.\u003c/p\u003e\n\u003cp\u003eThe levels of both histamine and 1-methylhistamine were higher in the feces of DR dogs than in those of healthy dogs. In the GI system, histamine is typically derived from L-histidine by histidine decarboxylase (HDC) and is degraded by histamine-N-methyl transferase (HNMT) in the cytosol or by membrane-bound HNMT to 1-methylhistamine \u003csup\u003e23\u003c/sup\u003e. Histamine can either be produced by immune cells in the periphery of the host, such as mast cells or dendritic cells \u003csup\u003e24\u003c/sup\u003e or by certain types of bacteria \u003csup\u003e25\u003c/sup\u003e. Under normal physiological conditions, mast cells \u003csup\u003e26\u003c/sup\u003e and dendritic cells \u003csup\u003e27\u003c/sup\u003e can cross the blood-brain barrier (BBB), linking host-produced histamine in the periphery to histamine in the brain. In mammals, HDC is an enzyme dependent on pyridoxal-5-phosphate (PLP), i.e. the active form of vitamin B6 \u003csup\u003e28\u003c/sup\u003e, whereas bacterial HDC can use either pyruvoyl or PLP as a coenzyme \u003csup\u003e25\u003c/sup\u003e. Interestingly, the authors recently described a decreased PLP plasma concentration in the same study population of dogs with IE compared with healthy dogs, despite a standardized nutritional background \u003csup\u003e16\u003c/sup\u003e .The observed increase in fecal histamine/1-methylhistamine could be linked to the decrease of plasma PLP in dogs with IE. However, this decrease in PLP was observed in both MP and DR dogs, whereas the levels of fecal histamine and 1-methylhistamine were significantly increased in DR dogs only. The increase in \u003cem\u003eClostridium sensu stricto 1\u003c/em\u003e and \u003cem\u003eEscherichia-Shigella\u003c/em\u003e in dogs with DR might thus play a role in this, as these bacteria have the genetic potential to use pyruvoyl-dependent HDC\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003csup\u003e25\u003c/sup\u003e. Moreover, histamine sensing in \u003cem\u003eEscherichia coli (E.Coli)\u003c/em\u003e, a member of the \u003cem\u003eEscherichia-Shigella\u003c/em\u003e genus, increases the bacterial catabolism of short-chain fatty acids (SCFAs), thereby interfering with the regulatory role of SCFAs in the intestine \u003csup\u003e29\u003c/sup\u003e and promoting a proinflammatory environment. On the other hand, the increased fecal histamine could indicate decreased GI barrier integrity, leading to leakage of histamine. Hereby, the timing between last seizure and sampling could explain the difference between DR and MP, as acute effects on GI barrier integrity are expected, similar to what is seen after stroke in humans \u003csup\u003e30\u003c/sup\u003e. Regardless of the source, intestinal histamine contributes to peripheral inflammation via histamine H\u003csub\u003e2\u003c/sub\u003e receptors (H\u003csub\u003e2\u003c/sub\u003eRs), leading to BBB disruption and the recruitment of other immune cells, ultimately connecting the innate immune response in the intestines to the brain \u003csup\u003e31\u003c/sup\u003e. In the central nervous system however, a complex interaction between histamine, neural excitability and epilepsy exists, whereby the effect on seizure propagation in different animal models is dependent on the location and type of receptor (H\u003csub\u003e1,2,3\u0026nbsp;\u003c/sub\u003eor H\u003csub\u003e4\u003c/sub\u003eR) \u003csup\u003e32\u003c/sup\u003e. Several animal studies have shown that histamine decreases in different brain regions during focal and generalized seizures. Therefore, a protective effect of high brain histamine levels was suspected, although it is unclear how brain histamine levels flux during the different stages of the disease epilepsy \u003csup\u003e32\u003c/sup\u003e. The increased fecal histamine observed in DR dogs in our study is however unlikely to be related to central histamine, and an indirect effect on the CNS through peripheral inflammation is hypothesized.\u003c/p\u003e\n\u003cp\u003eInosine, which was decreased in the feces of DR compared to MP and healthy dogs, is a degradation product of adenosine. Adenosine metabolism increases under stressful conditions such as inflammation, producing more inosine. Inosine in turn acts as a signaling molecule that can modulate the immune system \u003csup\u003e33\u003c/sup\u003e. An increase in blood purines, i.e., inosine, hypoxanthine and xanthine, was correlated with seizure severity and neurodegeneration in mouse models \u003csup\u003e34\u003c/sup\u003e. In people with temporal lobe epilepsy, increased baseline (\u0026gt; 24 h following a seizure event) blood purine levels were found compared to those in controls \u003csup\u003e34\u003c/sup\u003e. Moreover, anti-epileptic properties for inosine have been described in different tonic‒clonic seizure animal models, including mice \u003csup\u003e35\u003c/sup\u003e and zebrafish \u003csup\u003e36\u003c/sup\u003e. Conversely, pro-epileptic properties for uric acid and inosine were found in a rat model of \u0026lsquo;absence seizures\u0026rsquo; \u003csup\u003e37\u003c/sup\u003e. The decrease in fecal inosine in DR dogs observed in our study suggests that more inosine is degraded by the GI microbiota or less inosine is excreted. A negative correlation was found between \u003cem\u003eCl. sensu stricto 1\u003c/em\u003e and hypoxanthine (Supplementary table S6), i.e. an inosine metabolite, which would be consistent with an increased microbial breakdown in DR dogs. On the other hand, if less inosine is excreted, more inosine is potentially metabolized to hypoxanthine, xanthine and uric acid or transported to the brain in dogs with DR IE. This may be linked to the perturbation of the taurine and hypotaurine pathways in IE, detected via pathway enrichment analysis, as taurine can attenuate xanthine oxidase \u003csup\u003e38\u003c/sup\u003e, the enzyme required to transform xanthine into uric acid \u003csup\u003e39\u003c/sup\u003e. Uric acid as such has been linked previously to cytotoxic brain injury and oxidative stress \u003csup\u003e40\u003c/sup\u003e, aspects that might contribute to DR in dogs.\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp;Metabolic alterations in feces of dogs with IE related to tryptophan metabolism.\u003c/p\u003e\n\u003cp\u003eAn increase in fecal serotonin was observed in MP compared to both DR and healthy dogs. Peripheral serotonin cannot cross the BBB under normal physiological conditions \u003csup\u003e41\u003c/sup\u003e. However, over 90% of the body\u0026rsquo;s serotonin is produced in the intestines, mainly by enterochromaffin (EC) cells, overflowing to the GI lumen and blood circulation \u003csup\u003e42\u003c/sup\u003e. Thus, the fecal serotonin detected in the current study corresponds to the leftover EC-produced serotonin pool. The EC serotonin pool targets primary afferent neurons in the GI tract, signaling nausea and discomfort from the GI tract to the brain, and regulating peristalsis and secretion in the GI tract \u003csup\u003e43\u003c/sup\u003e. Murine studies have shown that intestinal bacteria play a regulatory role in body serotonin levels \u003csup\u003e44\u003c/sup\u003e. More specifically, \u003cem\u003eE. coli\u003c/em\u003e can have the genetic ability to produce serotonin, in addition to PLP, tryptophan and indole \u003csup\u003e45\u003c/sup\u003e, and might therefore be involved in alterations in these metabolites. Previously, anticonvulsive properties and reduced mortality have been associated with higher CNS serotonin levels in humans and mice \u003csup\u003e46\u003c/sup\u003e. However, it is unclear whether the EC serotonin pool could have similar effects mediated by signaling from the GI system to the brain. It has been demonstrated that this signaling pathway involves the afferent fibers of the vagal nerve \u003csup\u003e47\u003c/sup\u003e, which is a common target for neuromodulation in epilepsy in both humans \u003csup\u003e48\u003c/sup\u003e and dogs \u003csup\u003e49\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eIndole, a bacterial degradation product of tryptophan, was negatively associated with the MSF in IE dogs and tryptophan as such tended to be positively associated with MSF. These associations could indicate greater bacterial degradation of tryptophan in dogs with a lower MSF. Thereby, indole enhances the intestinal epithelial barrier function \u003csup\u003e50\u003c/sup\u003e, which might reduce the leakage of inflammatory mediators to the peripheral circulation, and ultimately the CNS. Indole-3-carboxylic acid, another indole metabolite derived from tryptophan, was significantly lower in the feces of IE (both MP and DR) compared to healthy dogs. Simultaneously, higher serotonin levels were detected in MP (i.e. dogs with a lower MSF) than in DR dogs. Moreover, a negative correlation between tryptophan and \u003cem\u003eSegetella Copri\u003c/em\u003e and \u003cem\u003eSuccinivibrio spp\u003c/em\u003e., both decreased in MP dogs, was found, indicating that both spp. may be involved in the microbial turnover of tryptophan. Ultimately, we hypothesize that dogs with a lower MSF have greater turnover of tryptophan to serotonin and indole \u003csup\u003e43\u003c/sup\u003e, both exerting potential positive effects, i.e. stimulation of the vagal nerve and enhancement of the epithelial barrier, respectively.\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp;Fecal metabolic alterations differ between dogs with MP and DR IE.\u003c/p\u003e\n\u003cp\u003eCompared to those in healthy dogs, the metabolic alterations were different for dogs with DR and MP IE, revealing an interaction between seizure frequency, severity or response to ASM and the fecal metabolome/microbiome. This may be cause or consequence, i.e. the fecal metabolome and microbiome in MP IE dogs may have a protective effect, leading to a lower MSF and/or a better response to ASM. Previously, a study revealed that mice receiving fecal microbiota from an epileptic mouse showed an increase in seizure susceptibility compared to recipients of healthy microbiota \u003csup\u003e51\u003c/sup\u003e. Moreover, the presence of systemic inflammatory diseases has the capacity to aggravate epileptogenesis \u003csup\u003e52\u003c/sup\u003e. Therefore, the seizure characteristics in our study might be caused by the different GI metabolic environments. On the other hand, it is possible that peripheral alterations induced by the condition, such as inflammation, are less pronounced in MP compared to DR IE as a consequence of the milder phenotype. Epilepsy as such can increase the BBB permeability \u003csup\u003e53\u003c/sup\u003e, potentially attributing to systemic alterations beyond CNS involvement. Finally, the potential confounding effect of the time between the last epileptic seizure and sampling should be considered. This time interval was significantly lower in DR dogs, with a median time interval of 7 days compared to a median time interval of 118 days in MP dogs. A shorter interval may have resulted in more acute alterations caused by epileptic seizures compared to longer intervals in MP dogs; where no acute effects are presumed.\u003c/p\u003e\n\u003cp\u003e4.\u0026nbsp; \u0026nbsp;Microbial alterations in feces of dogs with IE.\u003c/p\u003e\n\u003cp\u003eCompared with those of healthy dogs, the feces of dogs with MP and DR presented significantly altered differential abundances of multiple bacterial genera. These alterations were different for each group; however, no significant differences were observed when the fecal microbiome compositions of DR and MP dogs were compared directly. Interestingly, all alterations found in our study, both for MP and DR dogs, were also observed previously in dogs with idiopathic inflammatory bowel disease (IBD), in comparison to healthy dogs \u003csup\u003e54\u003c/sup\u003e. Although alterations in microbial composition differ between dogs and humans \u003csup\u003e55\u003c/sup\u003e, a similar IBD pathophysiology comprising an immune-mediated basis, influenced by genetic and environmental factors, has been proposed \u003csup\u003e56\u003c/sup\u003e. Further similarities with IBD could be substantiated when evaluating the metabolic fingerprint, whereby our study putatively showed altered primary bile acid biosynthesis in dogs with IE. Whereas in dogs with IBD, one of the major metabolic alterations included a decrease in secondary bile acids, i.e., deconjugated primary bile acids formed by the intestinal microbiome \u003csup\u003e57\u003c/sup\u003e. According to a human population-based study, IBD increases the risk for epilepsy, with an adjusted hazard ratio of 1.30 \u003csup\u003e58\u003c/sup\u003e. Although there are, to the best of our knowledge, no studies linking IE and IBD in dogs, our fecal metabolome and microbiome findings support a bidirectional link between the CNS and an inflammatory GI environment.\u003c/p\u003e\n\u003cp\u003eCompared to those in healthy dogs, the abundances of the genera \u003cem\u003eClostridium sensu stricto 1\u0026nbsp;\u003c/em\u003eand \u003cem\u003eEscherichia-Shigella\u003c/em\u003e were greater in dogs with DR IE. The latter is in line with microbiome alterations in humans, whereby an increase was observed in adults with poststroke epilepsy \u003csup\u003e59\u003c/sup\u003e, in infants with epilepsy and comorbid diarrhea \u003csup\u003e60\u003c/sup\u003e, in children with focal epilepsy in the pretreatment phase \u003csup\u003e61\u003c/sup\u003e, as well as in an adult epilepsy cohort \u003csup\u003e62\u003c/sup\u003e. Moreover, a shift toward reduced carbohydrate metabolism, linked to an increase in the \u003cem\u003eEscherichia\u003c/em\u003e genus, was observed in children with severe epilepsy on a ketogenic diet, raising concerns about the functional microbial alterations caused by this type of diet \u003csup\u003e63\u003c/sup\u003e. However, in IE dogs receiving a specific type of ketogenic diet, i.e., medium chain triglycerides (MCTs), no significant alterations in the genus Escherichia have been noted \u003csup\u003e64,65\u003c/sup\u003e. Interestingly, in the latter of these MCT dog studies, lower levels of the \u003cem\u003eBlautia\u003c/em\u003e genus were detected in DR \u003cem\u003evs.\u003c/em\u003e MP dogs at baseline \u003csup\u003e65\u003c/sup\u003e, whereas in our study, \u003cem\u003eBlautia hominis\u003c/em\u003e was increased in MP compared to healthy dogs. In the MCT dog study by Pilla and colleagues, a decrease in \u003cem\u003eBlautia spp\u003c/em\u003e. compared with the baseline was observed in both the placebo and MCT-diet groups \u003csup\u003e64\u003c/sup\u003e. However, no conclusion could be drawn regarding the reason for this decrease. In humans, \u003cem\u003eBlautia\u003c/em\u003e \u003cem\u003espp\u003c/em\u003e. are generally considered to have anti-inflammatory properties \u003csup\u003e66,67\u003c/sup\u003e. A generalized conclusion of effects at the genus level should be avoided but considered at the species or even strain level \u003csup\u003e68\u003c/sup\u003e. In the context of the gut‒brain axis, \u003cem\u003eBlautia hominis\u0026nbsp;\u003c/em\u003ewas more abundant in an elderly human population not experiencing postoperative delirium (n = 20) compared to elderly people experiencing postoperative delirium (n = 20) \u003csup\u003e69\u003c/sup\u003e, suggesting a positive effect in the context of MGBA communication.\u003c/p\u003e\n\u003cp\u003eSurprisingly, at the ASV phylogenetic level, only significantly different ASVs were found between MP and healthy dogs. \u0026nbsp;\u003cem\u003eSegetella Copri DSM 18205\u003c/em\u003e, whose abundance was decreased in MP dog feces, has been shown to produce proinflammatory cytokines and promote a Th-17-mediated immune response \u003cem\u003ein vitro\u0026nbsp;\u003c/em\u003e\u003csup\u003e70,71\u003c/sup\u003e. This further substantiates our hypothesis that MP dogs exhibit fewer proinflammatory characteristics in their intestinal environment than DR dogs. Dogs with MP IE also presented a lower abundance of \u003cem\u003ePhascolarctobacterium succinatutens\u003c/em\u003e and \u003cem\u003eSuccinivibrio\u003c/em\u003e spp., both of which are involved in propionate production in dogs \u003csup\u003e72\u003c/sup\u003e. Propionate, as such, is important in the regulation of hepatic lipid metabolism and satiety in the host \u003csup\u003e73\u003c/sup\u003e. It could be hypothesized that the ASV alterations in MP dogs are therefore potentially related to a positive response to ASM.\u003c/p\u003e\n\u003cp\u003e5.\u0026nbsp; \u0026nbsp;Study strengths and limitations\u003c/p\u003e\n\u003cp\u003eThe strengths of our study are the simultaneous analysis of both fecal metabolomics and microbiomics, providing an in-depth characterization of changes in the GI system of IE compared to healthy dogs. To the best of our knowledge, multi-omics integration at this level has been performed only once in subjects with naturally occurring epilepsy, i.e., children with DR epilepsy \u003csup\u003e74\u003c/sup\u003e. Our study is the first in dogs, as well as the first to include an MP group, as well as standardized nutrition, hence excluding interfering dietary effects. In the microbiome, functional redundancy is typically present, emphasizing the importance of the role for specific bacteria in addition to their phylogenetic composition. Our study attempted to include functional information by combining microbiome and metabolome data. However, complex interactions among the host, intestinal microbiome and metabolites exist, challenging the biological interpretation of the data. In the present study, few meaningful interactions between microbial species and metabolites could be revealed. Therefore, future studies should attempt to expand microbiome analysis by e.g. including functional protein analysis, like PICRUSt \u003csup\u003e75\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eSince all dogs with IE except 3 received ASM at the time of sampling, ASM is considered as an important confounder. Future research should therefore aim to include drug-na\u0026iuml;ve dogs and evaluate the effects of ASM on the fecal metabolome and microbiome. Furthermore, the time between the last seizure and sampling is another important confounder, especially in the comparison between MP and DR dogs. Future studies should consider multiple sampling timepoints related to the last seizure in dogs with IE to discriminate acute seizure effects from chronic alterations.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eDogs with IE presented an altered fecal metabolic fingerprint and profile, and differences in microbiome composition compared to healthy dogs (on a standardized nutritional background). Overall, the feces of dogs with DR IE presented alterations suggesting a proinflammatory GI environment, i.e. an increase in histamine and 1-methylhistamine, and a decrease in inosine, as well as elevated \u003cem\u003eEscherichia-Shigella\u003c/em\u003e and \u003cem\u003eClostridium sensu stricto 1\u003c/em\u003e. In contrast, the feces of dogs with MP IE revealed increased serotonin and inosine compared to healthy and DR dogs. In addition, \u003cem\u003eBlautia hominis\u003c/em\u003e was increased, whereas the genera \u003cem\u003eSuccinivibrio\u003c/em\u003e and \u003cem\u003ePhascolarctobacterium\u003c/em\u003e were decreased. The noted changes have previously been linked to positive GI health effects, including anti-inflammatory properties and enhanced epithelial barrier function.\u003c/p\u003e \u003cp\u003eOur study suggests a role for the MGBA in the pathophysiology of canine epilepsy, potentially influencing the response to ASM and/or seizure frequency. Our multi-omics approach also unraveled novel metabolic pathways of interest, including histamine and tryptophan metabolism, which could be further exploited in future targeted research and intervention studies.\u003c/p\u003e \u003c/div\u003e "},{"header":"MATERIALS AND METHODS","content":"\u003cp\u003e1. \u0026nbsp; \u0026nbsp;Study design and subjects\u003c/p\u003e\n\u003cp\u003eThe study protocol (Fig. 5), approved by the Ethical Committee of Veterinary Medicine and Bioscience Engineering, Ghent University (EC2020-091), included three groups of client-owned dogs: healthy dogs, MP IE dogs, and DR IE dogs. The inclusion criteria for all dogs included anamnesis, unremarkable general physical and neurological exams, and no abnormalities on blood or urine tests. The BCS was recorded on a 9-point scale, with 4\u0026ndash;5 points considered ideal \u003csup\u003e76\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 5: Study protocol.\u003c/strong\u003e\u0026nbsp; HC: Healthy controls; MP: mild phenotype idiopathic epilepsy; DR: drug resistant idiopathic epilepsy; UHPLC-HRMS: ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. This figure was created by the authors using biorender.com.\u003c/p\u003e\n\u003cp\u003eFor dogs with IE, alterations in liver enzymes (ALT, ALP) and electrolytes (K, Na, Cl) without clinical relevance and related to ASM were retained. No antibiotics were allowed three months prior to sample collection. IE diagnosis followed the International Veterinary Epilepsy Taskforce guidelines, i.e. Tier I (based on signalment, medical history, video evaluation of a seizure and routine blood examination) or II (Tier I + bile acids, MRI and cerebrospinal fluid evaluation) \u003csup\u003e17\u003c/sup\u003e. An epileptic seizure diary for three months prior to the start of the study was needed, allowing the classification of dogs. Within the MP group dogs with \u0026le;1 seizure/ 3 months and no status epilepticus nor cluster seizures, and dogs with a good response to ASM, i.e. \u0026gt;50% seizure reduction post-ASM adjustment, were included. Whereas dogs were categorized as DR if there was failure to achieve \u0026gt;50% seizure reduction despite \u0026ge;2 ASMs for \u0026ge;2 months \u003csup\u003e77\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eAll dogs received an adult maintenance diet (Purina\u0026reg; Proplan\u0026reg; Medium Adult with Optibalance) and treats (Purina\u0026reg; Proplan\u0026reg; Dental Probar) per FEDIAF 2019 guidelines based on maintenance energy requirements (MER). The owners were instructed to adhere strictly to the provided diet for at least 20 days. Freshly voided fecal samples were collected within 15 minutes, frozen, and stored for a maximum of 24 h at home by the owners until cooled transport. After arrival at the research facility, samples were aliquoted for DNA extraction and 16S rRNA sequencing (stored at -20\u0026deg;C), as well as for metabolome analysis (stored at -80\u0026deg;C). Fecal aliquots for metabolome analysis were subjected to 72 h of lyophilization to eliminate microbial activity and facilitate homogenization. Plasma samples from the same study were collected and analyzed, of. which results were published previously \u003csup\u003e16\u003c/sup\u003e .\u003c/p\u003e\n\u003cp\u003e2. \u0026nbsp; \u0026nbsp;Metabolomics analysis\u003c/p\u003e\n\u003cp\u003eGeneric extraction, followed by UHPLC-HRMS analysis of the fecal metabolome, was performed via a validated extraction protocol and analysis method \u003csup\u003e78\u003c/sup\u003e. In-house standard mixtures of 371 metabolites (Supplementary Table S5) were used to validate the operational conditions, together with quality control (QC) samples prepared from a representative pool of fecal sample extracts (n = 50) and a negative control sample, i.e., a blank sample prepared following the extraction protocol. Standard mixtures were injected at the beginning and end of the sequence. QC samples and a negative control sample were injected at the beginning, following every 10 biological samples and at the end of the sequence. Biological samples were analyzed in a randomized order \u003csup\u003e72\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e3. \u0026nbsp; \u0026nbsp;Microbiomics analysis\u003c/p\u003e\n\u003cp\u003eBacterial DNA for microbiome analysis was extracted via the QIAamp\u0026reg; PowerFecal Pro DNA extraction kit. One sample could not be included in the microbiome analysis owing to technical issues during DNA extraction (DR; dog 95), resulting in 87 analyzed fecal samples (39 healthy, 26 DR and 22 MP). Positive controls (n = 4; ZymoBIOMICS\u0026reg; Microbial Community Standard) were included to assess the quality of sample preprocessing and sequencing. Bacterial barcoding was conducted through a 2-step amplification process utilizing the primers S-D-Bact-0341-b-S-17 (5\u0026prime;-CCTACGGGNGGCWGCAG-3\u0026prime;) and S-D-Bact-0785-a-A-21 (5\u0026prime;-GACTACHVGGGTATCTAATCC-3\u0026prime;), which amplify the V3-V4 region of the 16S rRNA gene as previously described \u003csup\u003e79\u003c/sup\u003e. The final barcoded libraries were sequenced on two different runs via Illumina MiSeq v3 technology (2\u0026times;300 bp, paired-end) by Macrogen.\u003c/p\u003e\n\u003cp\u003e4. \u0026nbsp; \u0026nbsp;Data processing and statistical analysis\u003c/p\u003e\n\u003cp\u003e4.1. \u0026nbsp; Clinical parameters\u003c/p\u003e\n\u003cp\u003eClinical parameters are described as proportions (categorical data) or means \u0026plusmn; standard deviations. Furthermore, dogs are categorized as adult, senior or geriatric dogs based on their age and body weight, since small dog breeds are known to live longer than large dog breeds \u003csup\u003e80\u003c/sup\u003e. Categorical data were compared using a Pearson Chi-square test. Numerical data were analyzed using one-way ANOVA followed by a post-hoc Tukey\u0026rsquo;s test for normally distributed data or Kruskal-Wallis rank sum followed by Dunn\u0026rsquo;s test for non-normally distributed data. IE characteristics included the type of epileptic seizure (generalized tonic clonic seizure (gtcs) or focal seizure) \u003csup\u003e81\u003c/sup\u003e, presence of cluster seizures or status epilepticus in the medical history, age at seizure onset, time between sampling and last seizure, and MSF in the 3 months preceding sample collection. Within the IE dogs, numerical data were compared between MP and DR using an independent two-sided T-test or Mann-Whitney U test. For all statistical tests a P-value \u0026lt; 0.05 was considered significant. Details regarding the clinical parameters of the dogs included in the study can be found in Supplementary Table S1-4 and Verdoodt \u003cem\u003eet al\u003c/em\u003e., 2025 (Epilepsia) \u003csup\u003e16\u003c/sup\u003e, where the same population was used to elucidate plasma metabolome alterations in dogs with IE compared with healthy dogs.\u003c/p\u003e\n\u003cp\u003e4.2. \u0026nbsp; \u0026nbsp; \u0026nbsp;Metabolomics\u003c/p\u003e\n\u003cp\u003eBoth targeted metabolites and untargeted features were normalized via internal QCs (iQCs). After iQC normalization, only metabolites with a coefficient of variance (CV) \u0026lt; 30% in the QCs were retained for further analysis.\u003c/p\u003e\n\u003cp\u003e4.2.1. \u0026nbsp; Targeted metabolomics\u003c/p\u003e\n\u003cp\u003eFor the in-house available metabolite standards, peak areas were obtained via manual integration via Xcalibur\u003csup\u003eTM\u003c/sup\u003e 4.1 (Thermo Fisher Scientific, USA). Only metabolites with a signal-to-noise ratio \u0026gt; 3 in 90% of the samples were considered. Identification was achieved based on accurate mass (\u003cem\u003em/z\u003c/em\u003e value, considering both the molecular ion and C\u003csub\u003e13\u003c/sub\u003e-isotope) and retention time relative to that of an external standard (level I identification according to the Metabolomics Standards Initiative (MSI)) \u003csup\u003e18\u003c/sup\u003e. Further data processing was executed via Excel (Microsoft, USA) and R (v 4.2.3) \u003csup\u003e82\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eFirst, fecal metabolite levels were semi-quantitatively compared between groups, i.e., healthy, IE, IE MP or IE DR, via a univariate approach \u003csup\u003e83\u003c/sup\u003e. Three-group comparisons (healthy \u003cem\u003evs.\u003c/em\u003e MP \u003cem\u003evs\u003c/em\u003e. DR) were performed via one-way ANOVA for normally distributed metabolites or a Kruskal‒Wallis rank sum test for non-normally distributed metabolites. The significance (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) of each pairwise comparison, i.e. healthy \u003cem\u003evs\u003c/em\u003e. DR, healthy \u003cem\u003evs\u003c/em\u003e. MP and DR \u003cem\u003evs.\u003c/em\u003e MP, was then evaluated using a post hoc Tukey (following ANOVA) or Dunn (following Kruskal-Wallis) test.\u003c/p\u003e\n\u003cp\u003eSecond, a generalized linear model was built that included only samples from IE dogs to evaluate the influence of known metabolite levels on the MSF. Within this model, age, sex, BCS and the use (yes \u003cem\u003evs\u003c/em\u003e. no) of the most common ASM, i.e., phenobarbital, potassium bromide and levetiracetam, were added as confounders. The results of the model include an estimate, i.e., an estimated change in the MSF for a one-unit change in each respective metabolite, assuming that all confounders are held constant, a standard error associated with this estimate and a \u003cem\u003eP\u003c/em\u003e\u003csub\u003elin\u003c/sub\u003e value, considered significant if \u003cem\u003eP\u003csub\u003elin\u003c/sub\u003e\u003c/em\u003e \u0026lt; 0.05 or a trend if 0.05 \u0026lt; \u003cem\u003eP\u003csub\u003elin\u003c/sub\u003e\u003c/em\u003e \u0026lt; 0.10. Positive estimates indicate higher fecal levels of the metabolite with a higher MSF.\u003c/p\u003e\n\u003cp\u003e4.2.2.\u0026nbsp; \u0026nbsp;Untargeted metabolomics\u003c/p\u003e\n\u003cp\u003eUntargeted data preprocessing was performed with Compound Discoverer (CD) 3.3 (Thermo Fisher Scientific, USA), combining positive and negative ions. The detected features were characterized by the \u003cem\u003em/z\u003c/em\u003e value (peak intensity threshold of 500.000 a.u., mass tolerance of 5 ppm), retention time (RT; maximum RT-shift of 0.4 min) and peak intensity (minimal signal-to-noise ratio of 3). Data preprocessing included log transformation and Pareto scaling. Further data processing was executed in Simca 17.1 (Umetrics AB, Sweden) and MetaboAnalyst 6.0 \u003csup\u003e84\u003c/sup\u003e. In Simca, an unsupervised multivariate PCA-X model (including the QC samples) was built for exploration of inherent sample variance and QC clustering. The sample data (excluding the QC samples) were then modeled via supervised OPLS-DA, whereby 4 pairwise comparisons were made: healthy \u003cem\u003evs.\u003c/em\u003e IE, healthy \u003cem\u003evs.\u003c/em\u003e DR, healthy \u003cem\u003evs\u003c/em\u003e. MP and DR \u003cem\u003evs\u003c/em\u003e. MP. The model parameters R\u003csup\u003e2\u003c/sup\u003e(Y) for fit, Q\u003csup\u003e2\u003c/sup\u003e(Y) for predictivity (both \u0026gt; 0.5), cross-validated analysis of variance (CV-ANOVA, \u003cem\u003eP\u0026nbsp;\u003c/em\u003evalue \u0026lt; 0.05) and permutation testing (n = 100) were assessed to evaluate model validity. The discriminative quality of features was investigated on the basis of variance importance in projection (VIP) scores \u0026gt; 1, S-plot correlations |p(corr)| \u0026gt; 0.4, and jackknife confidence intervals not across zero. In parallel, pathway enrichment analysis via the Mummichog and GSEA algorithms in MetaboAnalyst 6.0 was performed for each ionization method separately (without additional filtering steps in the MetaboAnalyst environment), and the fecal metabolome of IE (DR and MP) dogs was compared to that of healthy dogs. Putative identification was pursued whenever possible by matching measured \u003cem\u003em/z\u003c/em\u003e values (\u0026lt; 5 ppm difference) to theoretical \u003cem\u003em/z\u003c/em\u003e values and retention times in the Chemspider or in-house database (level 2 identification according to MSI) \u003csup\u003e18\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e4.2 Microbiomics\u003c/p\u003e\n\u003cp\u003eThe demultiplexing of the amplicon dataset and the deletion of the barcodes were carried out by the sequencing provider. All further statistical analyses were performed in R (v 4.2.3) \u003csup\u003e82\u003c/sup\u003e. The raw sequence reads were trimmed, quality filtered and dereplicated via the dada2 package (v 1.24.0) \u003csup\u003e85\u003c/sup\u003e. First, an initial ASV table was constructed, followed by removal of the chimeras via the \u003cem\u003eremoveBimeraDenovo\u003c/em\u003e function. Second, the taxonomy was assigned via dada2\u0026rsquo;s na\u0026iuml;ve Bayesian classifier method on the basis of the Silva database (v 1.38) \u003csup\u003e86\u003c/sup\u003e. A phylogenetic tree was then constructed via the DECIPHER (v 2.24.0) algorithm \u003csup\u003e87\u003c/sup\u003e, after which a neighbor-joining tree was constructed via phangorn (v 2.10.0) \u003csup\u003e88\u003c/sup\u003e. The resulting phylogenetic tree and ASV table were loaded into phyloseq (v 1.38.0) \u003csup\u003e89\u003c/sup\u003e, whereby a minimal sequencing depth of 10 000 reads was achieved. Within the phyloseq package, alpha (Chao1 and Shannon) and beta (Jaccard, unweighted and weighted UniFrac) diversity indices were calculated and statistically compared between groups via PERMANOVA. Furthermore, ASVs whose total abundance was less than 0.01% and whose prevalence was less than 50% within a group were discarded before further analysis. Significantly (\u003cem\u003eP\u0026nbsp;\u003c/em\u003e\u0026lt; 0.05) differentially abundant bacterial taxa were identified at different phylogenetic levels by applying DESeq2 \u003csup\u003e90\u003c/sup\u003e to the resulting compositional data, considering the confounders sex, BCS and age category (adult, senior or geriatric). The taxonomy of significantly differentially abundant ASVs was checked by comparing the differentially abundant ASV sequences to multiple taxonomic databases via the Basic Local Alignment Search Tool (BLAST) \u003csup\u003e91\u003c/sup\u003e, whereby a minimal identical percentage of 98% was considered for identification.\u003c/p\u003e\n\u003cp\u003e4.3 Multi-omics integration\u003c/p\u003e\n\u003cp\u003eThe correlation between targeted metabolites and the microbiome was evaluated via Spearman\u0026rsquo;s correlation test \u003csup\u003e92\u003c/sup\u003e, resulting in a correlation coefficient \u0026rho; and a false discovery rate (FDR)-corrected \u003cem\u003eP\u003c/em\u003e value. A metabolite‒ASV correlation was considered significant when \u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05. Of these, only correlations where | \u0026rho; | \u0026gt; 0.4 were retained for biological interpretation. Additionally, significant pairs with differentially abundant ASVs and 0.4 \u0026gt; | \u0026rho; | \u0026gt; 0.2 were reported as supplementary information.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eACKNOWLEDGMENTS\u003c/p\u003e\n\u003cp\u003eF.V. (1S71421N) is supported as an SB PhD fellow by the Research Foundation\u0026ndash;Flanders (FWO). L.Y.H. (1297623N) is supported by the Research Foundation - Flanders (FWO).\u003c/p\u003e\n\u003cp\u003eThis study was financially supported by Nestl\u0026eacute; Purina Petcare Europe.\u003c/p\u003e\n\u003cp\u003eThe authors want to thank all the laboratory technicians working at the Laboratory of Integrative Metabolomics for their technical assistance during this project.\u003c/p\u003e\n\u003cp\u003eAUTHOR CONTRIBUTIONS\u003c/p\u003e\n\u003cp\u003eF.V. contributed to the conception and design of the study; the acquisition, analysis and interpretation of the data; and the drafting of the manuscript. L.Y.H. and M.H. contributed to the conception and design of the study; acquisition, analysis and interpretation of the data; and critical revision of the manuscript. L.V. and E.G. contributed to the analysis and interpretation of the data and critical revision of the manuscript. L.V.H., F.V.I. and S.F.M.B. contributed to the interpretation of the data and critical revision of the manuscript. All the authors have read and approved the final version of the manuscript.\u003c/p\u003e\n\u003cp\u003eDATA AVAILABILITY\u003c/p\u003e\n\u003cp\u003eData on the analytical standards and detailed clinical characteristics of the enrolled dogs are provided in the supplementary information. The raw data will be made available via https://www.ebi.ac.uk/metabolights/MTBLS10915.\u003c/p\u003e\n\u003cp\u003eCONFLICT OF INTEREST\u003c/p\u003e\n\u003cp\u003eF.V. is currently working on a doctoral research project, including the current study, regarding the role of the gastrointestinal microbiome and nutrition in canine IE, which is financially supported by Nestl\u0026eacute; Purina Petcare Europe. M.H. is a member of the Advisory Board of Nestl\u0026eacute; Purina Petcare. M.H. has been paid for several consulting services by a variety of pet food companies. The authors have no other financial or personal relationships with other people or organizations that could inappropriately influence or bias the content of the paper.\u003c/p\u003e\n\u003cp\u003eETHICAL DECLARATION\u003c/p\u003e\n\u003cp\u003eThis research was conducted in compliance with European legislation on animal experimentation (EU directive 2010/63/EU) and the ARRIVE guidelines. The study protocol was approved by the ethical committee of the Faculty of Veterinary Medicine and Bioscience Engineering, Ghent University (EC2020-091).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWorld Health Organization. \u003cem\u003eEPILEPSY A Public Health Imperative International League Against Epilepsy\u003c/em\u003e. (2019). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/about/licensing\u003c/span\u003e\u003cspan address=\"https://www.who.int/about/licensing\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAndualem, F. et al. Quality of life and associated factors among people with epilepsy in Ethiopia: a systematic review and meta-analysis. \u003cem\u003eBMC Public. Health\u003c/em\u003e \u003cb\u003e24\u003c/b\u003e, (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYadav, J., Singh, P., Dabla, S. \u0026amp; Gupta, R. Psychiatric comorbidity and quality of life in patients with epilepsy on anti-epileptic monotherapy and polytherapy. \u003cem\u003eTzu Chi Med. J.\u003c/em\u003e \u003cb\u003e34\u003c/b\u003e, 226\u0026ndash;231 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eL\u0026ouml;scher, W., Potschka, H., Sisodiya, S. M. \u0026amp; Vezzani, A. Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options. \u003cem\u003ePharmacol. Rev.\u003c/em\u003e \u003cb\u003e72\u003c/b\u003e, 606\u0026ndash;638 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSayyed, R. Z. \u0026amp; Khan, M. \u003cem\u003eMicrobiome-Gut-Brain Axis. Microbiome-Gut-Brain Axis: Implications on Health\u003c/em\u003e (Springer Nature Singapore, 2022). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/978-981-16-1626-6\u003c/span\u003e\u003cspan address=\"10.1007/978-981-16-1626-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, S. J. et al. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson\u0026rsquo;s Disease. \u003cem\u003eJ. Parkinsons Dis.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, 1219\u0026ndash;1230 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou, M. et al. Microbiome and tryptophan metabolomics analysis in adolescent depression: roles of the gut microbiota in the regulation of tryptophan-derived neurotransmitters and behaviors in human and mice. \u003cem\u003eMicrobiome\u003c/em\u003e 11, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJemimah, S., Chabib, C. M. M., Hadjileontiadis, L. \u0026amp; AlShehhi, A. Gut microbiome dysbiosis in Alzheimer\u0026rsquo;s disease and mild cognitive impairment: A systematic review and meta-analysis. \u003cem\u003ePLoS One\u003c/em\u003e \u003cb\u003e18\u003c/b\u003e, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGernone, F., Uva, A., Silvestrino, M., Cavalera, M. A. \u0026amp; Zatelli, A. Role of Gut Microbiota through Gut\u0026ndash;Brain Axis in Epileptogenesis: A Systematic Review of Human and Veterinary Medicine. \u003cem\u003eBiology (Basel)\u003c/em\u003e. \u003cb\u003e11\u003c/b\u003e, 1290 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChong, D., Jones, N. C., Schittenhelm, R. B., Anderson, A. \u0026amp; Casillas-Espinosa, P. M. Multi-omics integration and epilepsy: Towards a better understanding of biological mechanisms. \u003cem\u003eProgress in Neurobiology\u003c/em\u003e vol. 227 Preprint at (2023). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.pneurobio.2023.102480\u003c/span\u003e\u003cspan address=\"10.1016/j.pneurobio.2023.102480\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCharalambous, M. et al. Translational veterinary epilepsy: A win-win situation for human and veterinary neurology. \u003cem\u003eVet. J.\u003c/em\u003e \u003cb\u003e293\u003c/b\u003e, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eL\u0026ouml;scher, W. Dogs as a Natural Animal Model of Epilepsy. 9, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVermeulen, R., Schymanski, E. L., Barab\u0026aacute;si, A. L. \u0026amp; Miller, G. W. The exposome and health: Where chemistry meets biology. \u003cem\u003eSci. (1979)\u003c/em\u003e. \u003cb\u003e367\u003c/b\u003e, 392\u0026ndash;396 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eObeso, D., Zubeldia-Varela, E. \u0026amp; Villase\u0026ntilde;or, A. Uncovering the influence of diet and gut microbiota in human serum metabolome. \u003cem\u003eAllergy: Eur. J. Allergy Clin. Immunol.\u003c/em\u003e \u003cb\u003e76\u003c/b\u003e, 2306\u0026ndash;2308 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePotschka, H., Fischer, A., L\u0026ouml;scher, W. \u0026amp; Volk, H. A. Pathophysiology of drug-resistant canine epilepsy. \u003cem\u003eVet. J.\u003c/em\u003e 296\u0026ndash;297, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVerdoodt, F. et al. Plasma metabolome reveals altered oxidative stress, inflammation, and amino acid metabolism in dogs with idiopathic epilepsy. \u003cem\u003eEpilepsia\u003c/em\u003e \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/epi.18256\u003c/span\u003e\u003cspan address=\"10.1111/epi.18256\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2025).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Risio, L. et al. International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs. \u003cem\u003eBMC Vet. Res.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e, 148 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSumner, L. W. et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). \u003cem\u003eMetabolomics\u003c/em\u003e \u003cb\u003e3\u003c/b\u003e, 211\u0026ndash;221 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChemspider Hydroxyphenobarbital. (2024). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.chemspider.com/Chemical-Structure.9402\u003c/span\u003e\u003cspan address=\"https://www.chemspider.com/Chemical-Structure.9402\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003cem\u003ehtml?rid=059e1bed-43dd-4b1f-9b0e-1d4047b4d172\u003c/em\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChemspider. 1beta-hydroxycholic acid. (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChemspider \u0026amp; Boc-Asn. (2024). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.chemspider.com/Chemical-Structure.74037.html?rid=f685b552-e7b8-46e2-9b28-0efdf459\u003c/span\u003e\u003cspan address=\"https://www.chemspider.com/Chemical-Structure.74037.html?rid=f685b552-e7b8-46e2-9b28-0efdf459\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cem\u003ef\u003c/em\u003e581\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChemspider. 2-(2-Carboxyethyl)-4-methyl-5-pentyl-3-furoic acid. (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarnes, W. G. \u0026amp; Hough, L. B. Membrane-bound histamine N-methyltransferase in mouse brain: Possible role in the synaptic inactivation of neuronal histamine. \u003cem\u003eJ. Neurochem\u003c/em\u003e. \u003cb\u003e82\u003c/b\u003e, 1262\u0026ndash;1271 (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarcik, W. et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. \u003cem\u003eAllergy: Eur. J. Allergy Clin. Immunol.\u003c/em\u003e \u003cb\u003e74\u003c/b\u003e, 899\u0026ndash;909 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMou, Z., Yang, Y., Hall, A. B. \u0026amp; Jiang, X. The taxonomic distribution of histamine-secreting bacteria in the human gut microbiome. \u003cem\u003eBMC Genom.\u003c/em\u003e \u003cb\u003e22\u003c/b\u003e, (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSilverman, A. J., Sutherland, A. K., Wilhelm, M. \u0026amp; Silver, R. Mast Cells Migrate from Blood to Brain. \u003cem\u003eJ. Neurosci.\u003c/em\u003e \u003cb\u003e20\u003c/b\u003e, 401\u0026ndash;408 (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConstant, O. et al. Role of Dendritic Cells in Viral Brain Infections. \u003cem\u003eFrontiers in Immunology\u003c/em\u003e vol. 13 Preprint at (2022). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fimmu.2022.862053\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2022.862053\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoya-Garcia, A. A., Medina, M. \u0026Aacute;. \u0026amp; S\u0026aacute;nchez-Jim\u0026eacute;nez, F. Mammalian histidine decarboxylase: From structure to function. \u003cem\u003eBioEssays\u003c/em\u003e vol. 27 57\u0026ndash;63 Preprint at (2005). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/bies.20174\u003c/span\u003e\u003cspan address=\"10.1002/bies.20174\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKrell, T. et al. Histamine: A bacterial signal molecule. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e vol. 22 Preprint at (2021). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/ijms22126312\u003c/span\u003e\u003cspan address=\"10.3390/ijms22126312\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConesa, M. P. B. et al. Stabilizing histamine release in gut mast cells mitigates peripheral and central inflammation after stroke. \u003cem\u003eJ. Neuroinflammation\u003c/em\u003e \u003cb\u003e20\u003c/b\u003e, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlasco, M. P. et al. Age-dependent involvement of gut mast cells and histamine in post-stroke inflammation. \u003cem\u003eJ. Neuroinflammation\u003c/em\u003e \u003cb\u003e17\u003c/b\u003e, (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang, L., Wang, Y. \u0026amp; Chen, Z. Central histaminergic signalling, neural excitability and epilepsy. \u003cem\u003eBritish Journal of Pharmacology\u003c/em\u003e vol. 179 3\u0026ndash;22 Preprint at (2022). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/bph.15692\u003c/span\u003e\u003cspan address=\"10.1111/bph.15692\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNascimento, F. P., Macedo-J\u0026uacute;nior, S. J., Lapa-Costa, F. R., Cezar-dos-Santos, F. \u0026amp; Santos, A. R. S. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor? \u003cem\u003eFrontiers in Neuroscience\u003c/em\u003e vol. 15 Preprint at (2021). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fnins.2021.703783\u003c/span\u003e\u003cspan address=\"10.3389/fnins.2021.703783\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeamer, E. et al. Elevated blood purine levels as a biomarker of seizures and epilepsy. \u003cem\u003eEpilepsia\u003c/em\u003e \u003cb\u003e62\u003c/b\u003e, 817\u0026ndash;828 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGanzella, M., Faraco, R. B., Almeida, R. F., Fernandes, V. F. \u0026amp; Souza, D. O. Intracerebroventricular administration of inosine is anticonvulsant against quinolinic acid-induced seizures in mice: An effect independent of benzodiazepine and adenosine receptors. \u003cem\u003ePharmacol. Biochem. Behav.\u003c/em\u003e \u003cb\u003e100\u003c/b\u003e, 271\u0026ndash;274 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrillatz, T. et al. Zebrafish-based identification of the antiseizure nucleoside inosine from the marine diatom Skeletonema marinoi. \u003cem\u003ePLoS One\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLakatos, R. K., Dobolyi, \u0026Aacute;. \u0026amp; Kov\u0026aacute;cs, Z. Uric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats. \u003cem\u003eBrain Res.\u003c/em\u003e \u003cb\u003e1686\u003c/b\u003e, 1\u0026ndash;9 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaliou, S. et al. Protective role of taurine against oxidative stress (Review). \u003cem\u003eMolecular Medicine Reports\u003c/em\u003e vol. 24 Preprint at (2021). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3892/mmr.2021.12242\u003c/span\u003e\u003cspan address=\"10.3892/mmr.2021.12242\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSekizuka, H. Uric acid, xanthine oxidase, and vascular damage: potential of xanthine oxidoreductase inhibitors to prevent cardiovascular diseases. \u003cem\u003eHypertension Research\u003c/em\u003e vol. 45 772\u0026ndash;774 Preprint at (2022). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41440-022-00891-7\u003c/span\u003e\u003cspan address=\"10.1038/s41440-022-00891-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAment, Z., Bevers, M. B., Wolcott, Z., Kimberly, W. T. \u0026amp; Acharjee, A. Uric Acid and Gluconic Acid as Predictors of Hyperglycemia and Cytotoxic Injury after Stroke. \u003cem\u003eTransl Stroke Res.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, 293\u0026ndash;302 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgus, A., Planchais, J. \u0026amp; Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. \u003cem\u003eCell. Host Microbe\u003c/em\u003e. \u003cb\u003e23\u003c/b\u003e, 716\u0026ndash;724 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eErspamer, V. PHARMACOLOGY OF INDOLEALKYLAMINES. \u003cem\u003ePharmacol. Rev.\u003c/em\u003e \u003cb\u003e6\u003c/b\u003e, 425 (1954).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGershon, M. D. \u0026amp; Tack, J. The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. \u003cem\u003eGastroenterology\u003c/em\u003e \u003cb\u003e132\u003c/b\u003e, 397\u0026ndash;414 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. \u003cem\u003eCell\u003c/em\u003e \u003cb\u003e161\u003c/b\u003e, 264\u0026ndash;276 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAverina, O. V. et al. Bacterial metabolites of human gut microbiota correlating with depression. \u003cem\u003eInt. J. Mol. Sci.\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e, 1\u0026ndash;40 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePetrucci, A. N., Joyal, K. G., Purnell, B. S. \u0026amp; Buchanan, G. F. Serotonin and sudden unexpected death in epilepsy. \u003cem\u003eExp. Neurol.\u003c/em\u003e \u003cb\u003e325\u003c/b\u003e, 113145 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlackshaw, L. A. \u0026amp; Grundy, D. \u003cem\u003eEffects of 5-Hydroxytryptamine on Discharge of Vagal Mucosal Afferent Fibres from the Upper Gastrointestinal Tract of the Ferret\u003c/em\u003e. \u003cem\u003eJ. Auton. Nerv. Syst\u003c/em\u003e, \u003cb\u003e45\u003c/b\u003e (1993).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDibu\u0026eacute;-Adjei, M., Kamp, M. A. \u0026amp; Vonck, K. 30 years of vagus nerve stimulation trials in epilepsy: Do we need neuromodulation-specific trial designs? \u003cem\u003eEpilepsy Research\u003c/em\u003e vol. 153 71\u0026ndash;75 Preprint at (2019). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.eplepsyres.2019.02.004\u003c/span\u003e\u003cspan address=\"10.1016/j.eplepsyres.2019.02.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarcourt-Brown, T. R. \u0026amp; Carter, M. Long-term outcome of epileptic dogs treated with implantable vagus nerve stimulators. \u003cem\u003eJ. Vet. Intern. Med.\u003c/em\u003e \u003cb\u003e37\u003c/b\u003e, 2102\u0026ndash;2108 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBansal, T., Alaniz, R. C., Wood, T. K. \u0026amp; Jayaraman, A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. \u003cem\u003eProc. Natl. Acad. Sci. U S A\u003c/em\u003e. \u003cb\u003e107\u003c/b\u003e, 228\u0026ndash;233 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMengoni, F. et al. Gut microbiota modulates seizure susceptibility. \u003cem\u003eEpilepsia\u003c/em\u003e \u003cb\u003e62\u003c/b\u003e, e153\u0026ndash;e157 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRana, A. \u0026amp; Musto, A. E. The role of inflammation in the development of epilepsy. \u003cem\u003eJournal of Neuroinflammation\u003c/em\u003e vol. 15 Preprint at (2018). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12974-018-1192-7\u003c/span\u003e\u003cspan address=\"10.1186/s12974-018-1192-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanael, E. et al. Blood-brain barrier dysfunction and decreased transcription of tight junction proteins in epileptic dogs. \u003cem\u003eJ. Vet. Intern. Med.\u003c/em\u003e \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/jvim.17099\u003c/span\u003e\u003cspan address=\"10.1111/jvim.17099\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD\u0026iacute;az-Rega\u0026ntilde;\u0026oacute;n, D. et al. Characterization of the Fecal and Mucosa-Associated Microbiota in Dogs with Chronic Inflammatory Enteropathy. (2023). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ani\u003c/span\u003e\u003cspan address=\"10.3390/ani\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eV\u0026aacute;zquez-Baeza, Y., Hyde, E. R., Suchodolski, J. S. \u0026amp; Knight, R. Dog and human inflammatory bowel disease rely on overlapping yet distinct dysbiosis networks. \u003cem\u003eNat. Microbiol.\u003c/em\u003e \u003cb\u003e1\u003c/b\u003e, 16177 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCerquetella, M. et al. Inflammatory bowel disease in the dog: Differences and similarities with humans. \u003cem\u003eWorld Journal of Gastroenterology\u003c/em\u003e vol. 16 1050\u0026ndash;1056 Preprint at (2010). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3748/wjg.v16.i9.1050\u003c/span\u003e\u003cspan address=\"10.3748/wjg.v16.i9.1050\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlake, A. B. et al. Altered microbiota, fecal lactate, and fecal bile acids in dogs with gastrointestinal disease. \u003cem\u003ePLoS One\u003c/em\u003e \u003cb\u003e14\u003c/b\u003e, (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, C. H., Lin, C. L. \u0026amp; Kao, C. H. Irritable bowel syndrome increases the risk of epilepsy a population-based study. \u003cem\u003eMed. (United States)\u003c/em\u003e. \u003cb\u003e94\u003c/b\u003e, 1\u0026ndash;7 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWei, D. et al. Identification of disordered profiles of gut microbiota and functional component in stroke and poststroke epilepsy. \u003cem\u003eBrain Behav.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu, T. et al. Altered intestinal microbiota composition with epilepsy and concomitant diarrhea and potential indicator biomarkers in infants. \u003cem\u003eFront. Microbiol.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou, C. et al. Changes and significance of gut microbiota in children with focal epilepsy before and after treatment. \u003cem\u003eFront. Cell. Infect. Microbiol.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCui, G. et al. Gut Microbiome Distinguishes Patients With Epilepsy From Healthy Individuals. \u003cem\u003eFront. Microbiol.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLindefeldt, M. et al. The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. \u003cem\u003eNPJ Biofilms Microbiomes\u003c/em\u003e \u003cb\u003e5\u003c/b\u003e, (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePilla, R. et al. The Effects of a Ketogenic Medium-Chain Triglyceride Diet on the Feces in Dogs With Idiopathic Epilepsy. \u003cem\u003eFront. Vet. Sci.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e, (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarc\u0026iacute;a-Belenguer, S., Grasa, L., Palacio, J., Moral, J. \u0026amp; Rosado, B. Effect of a Ketogenic Medium Chain Triglyceride-Enriched Diet on the Fecal Microbiota in Canine Idiopathic Epilepsy: A Pilot Study. \u003cem\u003eVet. Sci.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e, 245 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKalyana Chakravarthy, S. et al. Dysbiosis in the Gut Bacterial Microbiome of Patients with Uveitis, an Inflammatory Disease of the Eye. \u003cem\u003eIndian J. Microbiol.\u003c/em\u003e \u003cb\u003e58\u003c/b\u003e, 457\u0026ndash;469 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClarke, S. F. et al. Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge. \u003cem\u003ePLoS One\u003c/em\u003e \u003cb\u003e8\u003c/b\u003e, (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu, X. et al. Blautia\u0026mdash;a new functional genus with potential probiotic properties? \u003cem\u003eGut Microbes\u003c/em\u003e vol. 13 1\u0026ndash;21 Preprint at (2021). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1080/19490976.2021.1875796\u003c/span\u003e\u003cspan address=\"10.1080/19490976.2021.1875796\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu, H. et al. Preoperative Status of Gut Microbiota Predicts Postoperative Delirium in Patients With Gastric Cancer. \u003cem\u003eFront. Psychiatry\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXiao, X., Singh, A., Giometto, A. \u0026amp; Brito, I. L. Segatella copri strains adopt distinct roles within a single individual\u0026rsquo;s gut. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1101/2024.05.20.595015\u003c/span\u003e\u003cspan address=\"10.1101/2024.05.20.595015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLarsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease. \u003cem\u003eImmunology\u003c/em\u003e vol. 151 363\u0026ndash;374 Preprint at (2017). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/imm.12760\u003c/span\u003e\u003cspan address=\"10.1111/imm.12760\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMackei, M. et al. Altered Intestinal Production of Volatile Fatty Acids in Dogs Triggered by Lactulose and Psyllium Treatment. \u003cem\u003eVet. Sci.\u003c/em\u003e \u003cb\u003e9\u003c/b\u003e, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWeitkunat, K. et al. Importance of propionate for the repression of hepatic lipogenesis and improvement of insulin sensitivity in high-fat diet-induced obesity. \u003cem\u003eMol. Nutr. Food Res.\u003c/em\u003e \u003cb\u003e60\u003c/b\u003e, 2611\u0026ndash;2621 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGong, X. et al. Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets. \u003cem\u003eMicrob. Pathog\u003c/em\u003e. \u003cb\u003e155\u003c/b\u003e, 104899 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDouglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. \u003cem\u003eNat. Biotechnol.\u003c/em\u003e \u003cb\u003e38\u003c/b\u003e, 685\u0026ndash;688 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLaflamme, D. Developmental and validation of a body condition score system for dogs. \u003cem\u003eCanine Pract.\u003c/em\u003e \u003cb\u003e22\u003c/b\u003e, 10\u0026ndash;15 (1997).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePotschka, H. et al. International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy. \u003cem\u003eBMC Vet. Res.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e, 1\u0026ndash;13 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Paepe, E. et al. A validated multi-matrix platform for metabolomic fingerprinting of human urine, feces and plasma using ultra-high performance liquid-chromatography coupled to hybrid orbitrap high-resolution mass spectrometry. \u003cem\u003eAnal. Chim. Acta\u003c/em\u003e. \u003cb\u003e1033\u003c/b\u003e, 108\u0026ndash;118 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoossens, E. et al. Acute Endotoxemia-Induced Respiratory and Intestinal Dysbiosis. \u003cem\u003eInt. J. Mol. Sci.\u003c/em\u003e \u003cb\u003e23\u003c/b\u003e, (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFortney, W. D. Implementing a Successful Senior/Geriatric Health Care Program for Veterinarians, Veterinary Technicians, and Office Managers. \u003cem\u003eVeterinary Clin. North. Am. - Small Anim. Pract.\u003c/em\u003e \u003cb\u003e42\u003c/b\u003e, 823\u0026ndash;834 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerendt, M. et al. International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. \u003cem\u003eBMC Vet. Res.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e, (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eR Core Team. R: A language and environment for statistical computing. Preprint at (2021). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.r-project.org/\u003c/span\u003e\u003cspan address=\"https://www.r-project.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ehttps://\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003egithub.com/UGent-LIMET/Univariate_analysis\u003c/span\u003e\u003cspan address=\"http://github.com/UGent-LIMET/Univariate_analysis\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXia, J. \u0026amp; Wishart, D. S. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. \u003cem\u003eNat. Protoc.\u003c/em\u003e \u003cb\u003e6\u003c/b\u003e, 743\u0026ndash;760 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCallahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. \u003cem\u003eNat. Methods\u003c/em\u003e. \u003cb\u003e13\u003c/b\u003e, 581\u0026ndash;583 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQuast, C. et al. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. \u003cem\u003eNucleic Acids Res.\u003c/em\u003e \u003cb\u003e41\u003c/b\u003e, (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWright, E. S. DECIPHER: Harnessing local sequence context to improve protein multiple sequence alignment. \u003cem\u003eBMC Bioinform.\u003c/em\u003e \u003cb\u003e16\u003c/b\u003e, (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchliep, K. P. phangorn: Phylogenetic analysis in R. \u003cem\u003eBioinformatics\u003c/em\u003e 27, 592\u0026ndash;593 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcMurdie, P. J., Holmes, S. \u0026amp; Phyloseq An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. \u003cem\u003ePLoS One\u003c/em\u003e \u003cb\u003e8\u003c/b\u003e, (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLove, M. I., Huber, W. \u0026amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. \u003cem\u003eGenome Biol.\u003c/em\u003e \u003cb\u003e15\u003c/b\u003e, (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, Z., Schwartz, S., Wagner, L. \u0026amp; Miller, W. \u003cem\u003eA Greedy Algorithm for Aligning DNA Sequences\u003c/em\u003e. \u003cem\u003eJOURNAL OF COMPUTATIONAL BIOLOGY\u003c/em\u003e vol. 7 www.liebertpub.com (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ehttps://\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003egithub.com/UGent-LIMET/Correlation_analysis/tree/main\u003c/span\u003e\u003cspan address=\"http://github.com/UGent-LIMET/Correlation_analysis/tree/main\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Epilepsy, Gut-Brain-Axis, Metabolomics, Microbiomics, Canine","lastPublishedDoi":"10.21203/rs.3.rs-5953419/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5953419/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIdiopathic epilepsy (IE) is the most common chronic neurological disease in dogs, and a natural animal model for human epilepsy types with genetic and unknown etiology. The microbiota-gut-brain axis (MGBA) is a promising target for improving brain health in individuals where brain function is hampered. It's role in the pathophysiology of epilepsy remains however unclear. We aimed to identify differences in fecal metabolome and microbiome between healthy and dogs with IE. To this purpose, fecal samples of healthy (n\u0026thinsp;=\u0026thinsp;39) and dogs with IE (n\u0026thinsp;=\u0026thinsp;49) were metabolically profiled (n\u0026thinsp;=\u0026thinsp;148 metabolites) and fingerprinted (n\u0026thinsp;=\u0026thinsp;3690 features) using liquid chromatography coupled to mass spectrometry, and the bacterial phylogeny examined using 16S rRNA sequencing. Dogs with IE were categorized as drug-resistant (DR) (n\u0026thinsp;=\u0026thinsp;27) or mild phenotype (MP) (n\u0026thinsp;=\u0026thinsp;22). In dogs with DR IE, fecal metabolites such as histamine (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.022) and microbiome genera such as \u003cem\u003eEscherichia-Shigella\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.021) increased, associated with a proinflammatory environment. In dogs with MP IE, alterations associated with anti-inflammatory properties, such as increased fecal serotonin (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.034) and \u003cem\u003eBlautia hominis\u003c/em\u003e (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.012) were revealed. Overall, a role for the MGBA communication in canine IE was established.\u003c/p\u003e","manuscriptTitle":"The fecal metabolome and microbiome are altered in dogs with idiopathic epilepsy compared to healthy dogs","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-02-06 09:51:14","doi":"10.21203/rs.3.rs-5953419/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-02-17T09:54:41+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-02-17T09:23:55+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-02-04T09:23:07+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-02-03T19:21:29+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ca8d4303-c4ed-4624-8888-6e9d7d14d308","owner":[],"postedDate":"February 6th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":43813758,"name":"Health sciences/Neurology/Neurological disorders/Epilepsy"},{"id":43813759,"name":"Health sciences/Gastroenterology/Gastrointestinal system"},{"id":43813760,"name":"Health sciences/Medical research/Translational research"}],"tags":[],"updatedAt":"2025-08-07T07:30:05+00:00","versionOfRecord":{"articleIdentity":"rs-5953419","link":"https://doi.org/10.1038/s41598-025-09919-7","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-07-25 15:57:45","publishedOnDateReadable":"July 25th, 2025"},"versionCreatedAt":"2025-02-06 09:51:14","video":"","vorDoi":"10.1038/s41598-025-09919-7","vorDoiUrl":"https://doi.org/10.1038/s41598-025-09919-7","workflowStages":[]},"version":"v1","identity":"rs-5953419","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5953419","identity":"rs-5953419","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}